isavuconazole profile

isavuconazole : A 1,3-thiazole that is butan-2-ol which is substituted at positions 1, 2, and 3 by 1,2,4-triazol-1-yl, 2,5-difluorophenyl, and 4-(p-cyanophenyl)-1,3-thiazol-2-yl groups, respectively. It is an antifungal drug used for the treatment of invasive aspergillosis and invasive mucormycosis. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

ID Source	ID
PubMed CID	6918485
CHEMBL ID	409153
CHEBI ID	85979
SCHEMBL ID	939038
MeSH ID	M0496090

Synonym
ro-0094815
asp9766
4-[2-[(1r,2r)-2-(2,5-difluorophenyl)-2-hydroxy-1-methyl-3-(1,2,4-triazol-1-yl)propyl]thiazol-4-yl]benzonitrile
benzonitrile, 4-[2-[(1r,2r)-2-(2,5-difluorophenyl)-2-hydroxy-1-methyl-3-(1h-1,2,4-triazol-1-yl)propyl]-4-thiazolyl]-
isavuconazole
bal-4815
bal4815
bal-8557(pro-drug)
chebi:85979 ,
CHEMBL409153
4-[2-[(1r,2r)-2-(2,5-difluorophenyl)-2-hydroxy-1-methyl-3-(1h-1,2,4-triazol-1-yl)propyl]-4-thiazolyl]benzonitrile
4-[2-[(2r,3r)-3-(2,5-difluorophenyl)-3-hydroxy-4-(1,2,4-triazol-1-yl)butan-2-yl]-1,3-thiazol-4-yl]benzonitrile
241479-67-4
60uto373ke ,
ro 0094815
unii-60uto373ke
bal 4815
isavuconazole [inn]
S3722
4-(2-((2r,3r)-3-(2,5-difluorophenyl)-3-hydroxy-4-(1h-1,2,4-triazol-1-yl)butan-2-yl)-1,3-thiazol-4-yl)benzonitrile
isavuconazole [mi]
isavuconazole [who-dd]
4-{2-[(1r,2r)-2-(2,5-difluoro-phenyl)-2-hydroxy-1-methyl-3-[1,2,4]triazol-1-yl-propyl]-thiazol-4-yl }-benzonitrile
DDFOUSQFMYRUQK-RCDICMHDSA-N
4-{2-[(1r,2r)-2-(2,5-difluoro-phenyl)-2-hydroxy-1-methyl -3-[1,2,4]triazol-1-yl-propyl]-thiazol-4-yl}-benzonitrile
(2r,3r)-3-[4-(4-cyanophenyl)thiazol-2-yl]-1-(1h-1,2,4-triazol-1-yl)-2-(2,5-difluorophenyl)-butan-2-ol
CS-3492
DTXSID2058251 ,
SCHEMBL939038
4-{2-[(2r,3r)-3-(2,5-difluorophenyl)-3-hydroxy-4-(1h-1,2,4-triazol-1-yl)butan-2-yl]-1,3-thiazol-4-yl}benzonitrile
isavuconazol
isavuconazolum
4-(2-((2r,3r)-3-(2,5-difluorophenyl)-3-hydroxy-4-(1h-1,2,4-triazol-1-yl)butan-2-yl)thiazol-4-yl)benzonitrile
AC-31076
HY-14273
isavuconazole (inn)
D10750
AKOS027250772
1286730-05-9
mfcd06407745
J-015363
NCGC00390646-01
bal-4815;ro-0094815
bal-4815;bal4815;bal 4815;ro-0094815;ro0094815;ro 0094815
BCP07587
Q6079042
DB11633
AS-30128
CCG-269093
NCGC00390646-02
EX-A1785
isavuconazole; bal-4815; ro-0094815
4-(2-((2r,3r)-rel-3-(2,5-difluorophenyl)-3-hydroxy-4-(1h-1,2,4-triazol-1-yl)butan-2-yl)thiazol-4-yl)benzonitrile
A899541
bdbm50595118
j02ac05
dtxcid6032069
2r,3r)-3-[4-(4-cyanophenyl)thiazol-2-yl]-2-(2,5- difluorophenyl)-1-(1h-1,2,4-triazol-1-yl)butan-2-ol
EN300-7401534

Excerpt	Reference	Relevance
"Isavuconazole (BAL4815) is a promising novel broad-spectrum triazole in late-stage clinical development that has proven active in vitro against Aspergillus and Candida species. "	( In vitro antifungal activities of isavuconazole (BAL4815), voriconazole, and fluconazole against 1,007 isolates of zygomycete, Candida, Aspergillus, Fusarium, and Scedosporium species. Bouza, E; Guinea, J; Peláez, T; Recio, S; Torres-Narbona, M, 2008)	2.07
"Isavuconazole is a triazole with broad-spectrum activity against medically important fungal pathogens. "	( Pharmacokinetics and pharmacodynamics of a novel triazole, isavuconazole: mathematical modeling, importance of tissue concentrations, and impact of immune status on antifungal effect. Denning, DW; Hope, WW; Majithiya, J; Parmar, A; Sharp, A; Warn, PA, 2009)	2.04
"Isavuconazole is a triazole antifungal drug, approved for the treatment of invasive aspergillosis and mucormycosis. "	( Interaction between flucloxacillin and azoles: Is isavuconazole next? Debaveye, Y; Lagrou, K; Spriet, I; Van Daele, R; Vandenbriele, C; Vos, R; Wauters, J, 2021)	2.32
"Isavuconazole (ISA) is an alternative treatment for Aspergillus spp. "	( Safety and Effectiveness of Isavuconazole Treatment for Fungal Infections in Solid Organ Transplant Recipients (ISASOT Study). Berastegui, C; Bravo, C; Campany-Herrero, D; Castells, L; Deu, M; Gavaldà, J; Len, O; Los-Arcos, I; Márquez-Algaba, E; Martín-Gómez, MT; Monforte, A; Moreso, F; Nuvials, X; Sacanell, J; Sempere, A, 2022)	2.46
"Isavuconazole is a triazole antifungal drug that has shown good efficacy in human patients. "	( Pharmacokinetics of isavuconazole in healthy cats after oral and intravenous administration. Dear, JD; Wittenburg, LA; Woerde, DJ, 2022)	2.49
"Isavuconazole is an antifungal drug used for treatment of invasive fungal infections. "	( Isavuconazole plasma concentrations in critically ill patients during extracorporeal membrane oxygenation. Eller, P; Gringschl, Y; Hatzl, S; Hoenigl, M; Krause, R; Kriegl, L; Meinitzer, A; Muhr, T; Prattes, J; Reisinger, AC; Schilcher, G; Zurl, C, 2022)	3.61
"Isavuconazole is a convenient triazole antifungal agent with a broad antifungal spectrum. "	( Efficacy and safety of isavuconazole against deep-seated mycoses: A phase 3, randomized, open-label study in Japan. Akashi, K; Izumikawa, K; Kakeya, H; Kamei, K; Kanda, Y; Kimura, SI; Kishida, M; Kohno, S; Matsuda, M; Miyazaki, T; Miyazaki, Y; Mukae, H; Niki, Y; Ogawa, K; Okada, F; Suzuki, J; Takazono, T; Taniguchi, S; Tateda, K; Yoshida, M, 2023)	2.66
"Isavuconazole is a safe therapeutic option for IMD in SOT recipients, with efficacy comparable to other patient groups."	( Isavuconazole for the Treatment of Invasive Mold Disease in Solid Organ Transplant Recipients: A Multicenter Study on Efficacy and Safety in Real-life Clinical Practice. Aguado, JM; Bodro, M; Carratalà, J; Cordero, E; Fariñas, MDC; Fernández-Ruiz, M; Fortún, J; Goikoetxea, J; Gutiérrez Martín, I; Illaro, A; López-Viñau, T; Moreno, A; Muñoz, P; Ramos-Martínez, A; Rodriguez-Álvarez, R; Ruiz-Ruigómez, M; Sabé, N; Salto-Alejandre, S; Valerio, M; Vidal, E, 2023)	3.8
"Isavuconazole (ISA) is a new triazole antifungal agent that has shown promising efficacy in the prophylaxis and treatment of invasive fungal diseases."	( Clinical research advances of isavuconazole in the treatment of invasive fungal diseases. Feng, S; Shen, Y; Zhang, T, 2022)	1.73
"Isavuconazole is a triazole with broad-spectrum antifungal activity. "	( Post-hoc analysis of the safety and efficacy of isavuconazole in older patients with invasive fungal disease from the VITAL and SECURE studies. Aram, JA; Engelhardt, M; Hamed, K; Huang, JJ; Kovanda, LL; Yan, J, 2023)	2.61
"Isavuconazole is a novel triazole antifungal agent. "	( A systematic review and meta-analysis of efficacy and safety of isavuconazole for the treatment and prophylaxis of invasive fungal infections. Asai, N; Hagihara, M; Hirai, J; Iwamoto, T; Kato, H; Mikamo, H; Mori, N; Umemura, T; Yamagishi, Y, 2023)	2.59
"Isavuconazole is an antifungal which has been approved to treat IFIs, but it has not been approved to prevent IFIs."	( A plain language summary on preventing fungal infections with isavuconazole in people with blood-related conditions. Aram, JA; Bellmann, C; Hongmei, J; Inês, M; Macmillan, T; Penack, O; Ping, Y; Webb, N, 2023)	1.87
"Isavuconazole is a drug that remains largely unstudied, especially for fungal infections that develop at the site of a break in the skin, such as a wound. "	( Almeida-Paes, R; Almeida-Silva, F; Bernardes-Engemann, AR; Coelho, RA; Corrêa-Junior, D; Fichman, V; Frases, S; Freitas, DF; Galhardo, MC; Zancopé-Oliveira, RM, 2023)	2.35
"Isavuconazole (ISA) is a newer antifungal used in patients with history of hematologic malignancies and hematopoietic transplant and cellular therapies (HM/TCT). "	( Breakthrough invasive fungal infections on isavuconazole prophylaxis in hematologic malignancy & hematopoietic stem cell transplant patients. Anderson, A; Camargo, JF; Chandhok, NS; Jabr, R; Khatri, AM; Komanduri, K; Morris, MI; Natori, A; Natori, Y; Raja, M; Shah, SA, 2023)	2.62
"Isavuconazole is a broad-spectrum antifungal agent for the management of invasive fungal disease. "	( Population Pharmacokinetics of Total and Unbound Isavuconazole in Critically Ill Patients: Implications for Adaptive Dosing Strategies. Brüggemann, RJM; Debaveye, Y; Jansen, AME; Mertens, B; Schouten, J; Spriet, I; Ter Heine, R; Verweij, PE; Wauters, J, 2023)	2.61
"Isavuconazole is a broad-spectrum azole that is FDA-approved for the treatment of aspergillosis and mucormycosis; data on the use of isavuconazole for the treatment and prevention of other invasive fungal infections are limited. "	( Treatment Failure of Isavuconazole in a Patient with Cryptococcosis. Gandhi, TN; Linder, KA; Miceli, MH, 2019)	2.28
"Isavuconazole (ISV) is a recently approved azole with a promising interaction and safety profile."	( Successful Treatment of Severe Aspergillosis with Isavuconazole Therapy after Allogeneic Stem Cell Transplantation. Anguita, J; Bailén, R; Balsalobre, P; Buño, I; Diez-Martin, JL; Dorado, N; Guinea, J; Kwon, M; Machado, M; Oarbeascoa, G; Padilla, B; Pradillo, V; Sancho, M; Serrano, D, 2019)	1.49
"Isavuconazole is a new azole approved for adults with invasive aspergillosis and mucormycosis, with a favorable hepatic tolerability reported in Phase III trials. "	( Isavuconazole-induced Acute Liver Failure in a Pediatric Patient With Invasive Aspergillosis. Brivio, E; Foresti, S; Migliorino, GM; Rovelli, A; Verna, M; Zucchini, N, 2019)	3.4
"Isavuconazole is a novel triazole with broad-spectrum activity that has shown good blood-brain barrier penetration in animal models."	( Isavuconazole for the treatment of patients with invasive fungal diseases involving the central nervous system. Cornely, OA; Hamed, K; Heinz, WJ; Herbrecht, R; Maertens, J; Marty, FM; Rahav, G; Schwartz, S, 2020)	2.72
"Isavuconazole is a broad-spectrum triazole approved for treatment of invasive fungal infections (IFIs). "	( A Single-Center, Open-Label Trial of Isavuconazole Prophylaxis against Invasive Fungal Infection in Patients Undergoing Allogeneic Hematopoietic Cell Transplantation. Barker, J; Bogler, Y; Giralt, S; Gyurkocza, B; Lee, YJ; Papanicolaou, GA; Perales, MA; Seo, S; Shaffer, B; Stern, A; Su, Y; Tamari, R, 2020)	2.27
"Isavuconazole (ISAV) is an extended spectrum mold-active triazole and has superior tolerability and fewer significant drug-drug interactions compared with other triazoles."	( Isavuconazole as Primary Antifungal Prophylaxis in Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome: An Open-label, Prospective, Phase 2 Study. Bivins, CA; Borthakur, G; Bose, P; Daver, N; Estrov, Z; Huang, X; Kadia, TM; Kantarjian, HM; Konopleva, M; Kontoyiannis, DP; Marx, KR; Masarova, L; McCue, D; Naqvi, K; Pemmaraju, N; Pierce, SA; Qiao, W; Rausch, CR; Ravandi, F; Takahashi, K; Wiederhold, NP; Wurster, S; Yilmaz, M, 2021)	2.79
"Isavuconazole is a new triazole that has shown efficacy in adults for primary and salvage treatment of mucormycosis."	( Isavuconazole As Successful Salvage Therapy for Mucormycosis in Pediatric Patients. Ashkenazi-Hoffnung, L; Ben-Ami, R; Bilavsky, E; Fischer, S; Grisaru, G; Levy, I; Nahum, E; Novikov, A; Sadot, E; Scheuerman, O, 2020)	2.72
"Isavuconazole is a triazole antifungal available in IV and capsule formulation. "	( Achievement of clinical isavuconazole blood concentrations in transplant recipients with isavuconazonium sulphate capsules administered via enteral feeding tube. Anderson, AD; Andes, DR; Borlagdan, J; Davis, MR; Lepak, AJ; Marini, RV; McCreary, EK; Nguyen, MH; Rivosecchi, RM; Sacha, LM; Shields, RK; Silveira, FP, 2020)	2.31
"Isavuconazole is a newer broad-spectrum antifungal agent with promising efficacy and safety."	( Isavuconazole for the prophylaxis and treatment of invasive fungal disease: A single-center experience. Jacobs, SE; Rana, MM; Saunders-Hao, P; Vu, CA, 2021)	2.79
"Isavuconazole appears to be a promising alternative for prophylaxis and treatment of invasive fungal disease. "	( Isavuconazole for the prophylaxis and treatment of invasive fungal disease: A single-center experience. Jacobs, SE; Rana, MM; Saunders-Hao, P; Vu, CA, 2021)	3.51
"Isavuconazole is a cost-effective treatment compared to voriconazole for patients with possible IA for a willingness to pay threshold of 25,000€ per additional QALY."	( The cost-effectiveness of isavuconazole compared to voriconazole, the standard of care in the treatment of patients with invasive mould diseases, prior to differential pathogen diagnosis in Spain. Azanza, JR; Grau, S; López-Gómez, V; López-Ibáñez de Aldecoa, A; Peral, C; Rebollo, P; Vázquez, L, 2021)	2.36
"Isavuconazole (ISA) is a frequently used antifungal agent for the treatment of invasive fungal diseases (IFDs). "	( Principal-agent theory-based cost and reimbursement structures of isavuconazole treatment in German hospitals. Cornely, OA; Jeck, J; Kron, F; Lazzaro, C; Thielscher, C; Wingen-Heimann, SM, 2021)	2.3
"Isavuconazole is a broad-spectrum triazole for the treatment of invasive fungal disease (IFD)."	( Clinical experience with isavuconazole in healthy volunteers and patients with invasive aspergillosis in China, and the results from an exposure-response analysis. Aram, JA; Cao, G; Cornely, OA; Desai, A; Fayyad, R; Guo, X; Hamed, K; Wu, D; Zhang, J; Zhang, Y, 2021)	2.37
"Isavuconazole is a triazole antifungal drug, approved for the treatment of invasive aspergillosis and mucormycosis. "	( Concomitant use of isavuconazole and CYP3A4/5 inducers: Where pharmacogenetics meets pharmacokinetics. Brüggemann, RJ; Debaveye, Y; Dreesen, E; Elkayal, O; Guchelaar, HJ; Lagrou, K; Spriet, I; Van Bleyenbergh, P; Van Daele, R; Vermeersch, P; Vos, R, 2021)	2.39
"Isavuconazole is a safe and reliable antifungal agent in complex hematological patients, with relatively low hepatotoxicity and QTc interval shortening properties."	( Clinical Considerations of Isavuconazole Administration in High-Risk Hematological Patients: A Single-Center 5-Year Experience. Chalandon, Y; Glampedakis, E; Kronig, I; Masouridi-Levrat, S; Neofytos, D; Van Delden, C; Vernaz, N, 2021)	2.36
"Isavuconazole is a new triazole approved for the treatment of invasive aspergillosis. "	( Isavuconazole susceptibility of clinical Aspergillus fumigatus isolates and feasibility of isavuconazole dose escalation to treat isolates with elevated MICs. Brüggemann, RJM; Buil, JB; Meis, JF; Melchers, WJG; Mouton, JW; Verweij, PE; Wasmann, RE; Zoll, J, 2018)	3.37
"Isavuconazole is a new triazole antifungal agent with official indications for the treatment of invasive fungal infections caused by Aspergillus and Mucormycosis."	( A Review of the Clinical Pharmacokinetics and Pharmacodynamics of Isavuconazole. Wilby, KJ, 2018)	1.44
"Isavuconazole is a novel antifungal drug approved for the treatment of adults with invasive aspergillosis and mucormycosis. "	( Isavuconazole shortens the QTc interval. Bassetti, M; Cornely, OA; Dörfel, D; Hagel, S; Lehners, N; Mellinghoff, SC; Plis, A; Schalk, E; Vena, A, 2018)	3.37
"Isavuconazole is a new drug that shows promise in the adult population for the treatment of IMIs."	( Successful treatment of invasive mucormycosis with isavuconazole in pediatric patients. Barg, AA; Bartuv, M; Greenberg, G; Keller, N; Malkiel, S; Toren, A, 2018)	1.45
"Isavuconazole is a triazole antifungal agent for treatment of invasive aspergillosis and mucormycosis. "	( Validation of an Isavuconazole High-Performance Liquid Chromatography Assay in Plasma for Routine Therapeutic Drug Monitoring Applications. Karasch, I; Lakner, J; Mueller, SC; Wacke, R, 2018)	2.26
"Isavuconazole is a triazole previously shown to have potent in vitro activity against Aspergillus spp., Mucorales and Candida spp. "	( Isavuconazole is highly active in vitro against Candida species isolates but shows trailing effect. Bouza, E; Escribano, P; Gómez, A; Guinea, J; Marcos-Zambrano, LJ; Muñoz, P; Sánchez-Carrillo, C, 2018)	3.37
"Isavuconazole is a new triazole with an expanded-spectrum and potent activity against moulds and yeasts. "	( Evaluation of isavuconazole MIC strips for susceptibility testing of Aspergillus and Scedosporium species. Costanzo, CM; Oliveri, S; Palermo, CI; Scalia, G; Trovato, L, 2019)	2.32
"Isavuconazole is a new antifungal prodrug for the treatment of invasive aspergillosis and mucormycosis. "	( Isavuconazole Kinetic Exploration for Clinical Practice. Concordet, D; Darnaud, L; Debard, A; Gandia, P; Godet, C; Lamoureux, F; Martins, P; Pontier, S; Venisse, N, 2018)	3.37
"Isavuconazole (IVZ) is a newest generation triazole antifungal approved for the treatment of invasive aspergillosis (IA) in adult patients and for the treatment of invasive mucormycosis in adult patients for whom treatment with amphotericin B is inappropriate."	( Isavuconazole: Case Report and Pharmacokinetic Considerations. Girmenia, C; Goffredo, BM; Marchesi, F; Mengarelli, A; Menna, P; Minotti, G; Romano, A; Salvatorelli, E, 2018)	2.64
"Isavuconazole is a new antifungal triazole agent with excellent oral bioavailability, predictable and linear pharmacokinetics, good tolerance and low adverse effects."	( [Invasive aspergillosis in solid organ transplantation]. Aguado, JM; Silva, JT; Torre-Cisneros, J, )	0.85
"Isavuconazole is a new azole, structurally related to fluconazole and voriconazole, that presents a very high oral absorption with no first-pass effect which is not interfered by the presence of food, gastric pH modifications, or mucositis. "	( [Pharmacological profile of isavuconazole]. Azanza Perea, JR; Sádaba Díaz de Rada, B, )	1.87
"Isavuconazole is a broad-spectrum azole antifungal for the treatment of aspergillosis and mucormycosis."	( Therapeutic drug concentrations of isavuconazole following the administration of isavuconazonium sulfate capsules via gastro-jejunum tube: A case report. Adamsick, ML; Elshaboury, RH; Gandhi, RG; Gift, T; Kotton, CN; Mansour, MK, 2019)	1.51
"Isavuconazole is a recent extended-spectrum triazole with activity against yeasts. "	( Isavuconazole MIC distribution of 29 yeast species responsible for invasive infections (2015-2017). Boullié, A; Bretagne, S; Desnos-Ollivier, M; Dromer, F; Gautier, C; Lortholary, O, 2019)	3.4
"Isavuconazole (ISA) is an attractive candidate for primary mold-active prophylaxis in high-risk patients with hematologic malignancies or hematopoietic cell transplant (HCT) recipients. "	( Isavuconazole Prophylaxis in Patients With Hematologic Malignancies and Hematopoietic Cell Transplant Recipients. Fontana, L; Hakki, M; Lewis, JS; Noble, BN; Perlin, DS; Strasfeld, L; Zhao, Y, 2020)	3.44
"Isavuconazole is a new broad-spectrum triazole with a favorable pharmacokinetic and safety profile. "	( In vitro activities of isavuconazole and comparator antifungal agents tested against a global collection of opportunistic yeasts and molds. Castanheira, M; Jones, RN; Messer, SA; Pfaller, MA; Rhomberg, PR, 2013)	2.14
"Isavuconazole is an extended-spectrum triazole with in vitro activity against a wide variety of fungal pathogens. "	( Isavuconazole activity against Aspergillus lentulus, Neosartorya udagawae, and Cryptococcus gattii, emerging fungal pathogens with reduced azole susceptibility. Byrnes, E; Datta, K; Garcia-Effron, G; Marr, KA; Perlin, DS; Rhee, P; Staab, JF, 2013)	3.28
"Isavuconazole is a novel expanded-spectrum triazole, which has recently been approved by the FDA as an orphan drug to treat invasive aspergillosis and is currently being studied in phase III clinical trials for invasive candidiasis. "	( Determination of isavuconazole susceptibility of Aspergillus and Candida species by the EUCAST method. Arendrup, MC; Cuenca-Estrella, M; Gomez-Lopez, A; Howard, SJ; Lass-Flörl, C, 2013)	2.17
"Isavuconazole is a novel, broad-spectrum antifungal developed for the treatment of opportunistic fungal infections."	( A phase 2, randomized, double-blind, multicenter trial to evaluate the safety and efficacy of three dosing regimens of isavuconazole compared with fluconazole in patients with uncomplicated esophageal candidiasis. Azie, N; Ghannoum, M; Schmitt-Hoffmann, AH; Viljoen, J, 2015)	1.35
"Isavuconazole is a novel broad-spectrum triazole antifungal agent. "	( Safety and pharmacokinetics of isavuconazole as antifungal prophylaxis in acute myeloid leukemia patients with neutropenia: results of a phase 2, dose escalation study. Böhme, A; Cornely, OA; Schmitt-Hoffmann, A; Ullmann, AJ, 2015)	2.15
"Isavuconazole (ISA) is a new generation, broad-spectrum triazole that has a favorable spectrum of efficacy and is available in both intravenous and oral forms."	( The 'cephalosporin era' of triazole therapy: isavuconazole, a welcomed newcomer for the treatment of invasive fungal infections. Chitasombat, MN; Kontoyiannis, DP, 2015)	1.4
"Isavuconazole is a new extended-spectrum triazole with activity against yeasts, molds, and dimorphic fungi. "	( Isavuconazole: A New Broad-Spectrum Triazole Antifungal Agent. Kauffman, CA; Miceli, MH, 2015)	3.3
"Isavuconazole is a novel, broad-spectrum, antifungal azole. "	( Activity of Isavuconazole and Other Azoles against Candida Clinical Isolates and Yeast Model Systems with Known Azole Resistance Mechanisms. Coste, AT; Sanglard, D, 2016)	2.26
"Isavuconazole is a novel triazole with broad-spectrum antifungal activity. "	( Isavuconazole versus voriconazole for primary treatment of invasive mould disease caused by Aspergillus and other filamentous fungi (SECURE): a phase 3, randomised-controlled, non-inferiority trial. Aoun, M; Baddley, JW; Bow, EJ; Cornely, OA; Giladi, M; Heinz, WJ; Herbrecht, R; Hope, W; Karthaus, M; Kontoyiannis, DP; Lee, DG; Lee, M; Lortholary, O; Maertens, JA; Maher, RM; Marr, KA; Morrison, VA; Neofytos, D; Oren, I; Patterson, TF; Raad, II; Rahav, G; Schmitt-Hoffmann, AH; Selleslag, D; Shoham, S; Thompson, GR; Ullmann, AJ; Zeiher, B, 2016)	3.32
"Isavuconazole is a new azole antifungal drug with a broad antifungal spectrum that includes yeasts, molds and dimorphic fungi. "	( Isavuconazonium sulfate for the treatment of fungal infection. Temesgen, Z; Walker, RC; Zeuli, JD, 2016)	1.88
"Isavuconazole is a triazole active in vitro and in animal models against moulds of the order Mucorales."	( Isavuconazole treatment for mucormycosis: a single-arm open-label trial and case-control analysis. Alangaden, GJ; Brown, JM; Chetchotisakd, P; Cornely, OA; Engelhardt, M; Fredricks, DN; Heinz, WJ; Herbrecht, R; Ito, M; Jaruratanasirikul, S; Kanj, SS; Kaufhold, A; Klimko, N; Klyasova, G; Lee, M; Maertens, JA; Maher, RM; Marty, FM; Melinkeri, SR; Mullane, KM; Oren, I; Ostrosky-Zeichner, L; Pappas, PG; Perfect, JR; Ráčil, Z; Rahav, G; Santos, R; Sasse, C; Schwartz, S; Thompson, GR; Vehreschild, JJ; Vehreschild, MJGT; Young, JH; Zeiher, B, 2016)	2.6
"Isavuconazole (ISAV) is a novel, broad-spectrum, triazole antifungal agent (IV and by mouth [PO]) developed for the treatment of IFD."	( Isavuconazole Treatment of Cryptococcosis and Dimorphic Mycoses. Azie, N; Cornely, OA; Engelhardt, M; Kovanda, L; Lee, M; Maher, R; Ostrosky-Zeichner, L; Perfect, JR; Queiroz-Telles, F; Rendon, A; Ribeiro Dos Santos, R; Thompson, GR; Vazquez, JA, 2016)	2.6
"Isavuconazole is a triazole currently approved not only for use in invasive aspergillosis and mucormycosis but also has demonstrable activity against Candida species and other common fungal pathogens. "	( Isavuconazonium sulfate: a triazole prodrug for invasive fungal infections. Bossaer, JB; Carico, R; Cluck, D; Harirforoosh, S; Murrell, D, 2017)	1.9
"Isavuconazole is a new triazole with broad-spectrum antifungal activity including invasive aspergillosis and mucormycosis."	( Isavuconazonium sulfate: a triazole prodrug for invasive fungal infections. Bossaer, JB; Carico, R; Cluck, D; Harirforoosh, S; Murrell, D, 2017)	1.9
"Isavuconazole is a second-generation triazole with activity against a broad spectrum of clinically important fungi. "	( Isavuconazole: A Review in Invasive Aspergillosis and Mucormycosis. Scott, LJ; Shirley, M, 2016)	3.32
"Isavuconazole is a cost-effective option for the treatment of IA among hospitalized patients."	( Cost-Effectiveness Analysis of Isavuconazole vs. Voriconazole as First-Line Treatment for Invasive Aspergillosis. Azie, N; Harrington, R; Lee, E; Messali, A; Spalding, J; Wei, J; Wu, EQ; Yang, H, 2017)	2.18
"Isavuconazole (ISAV) is a new mucormycosis treatment."	( The cost of treating mucormycosis with isavuconazole compared with standard therapy in the UK. Bagshaw, E; Blackney, M; Cornely, OA; Escrig, C; Heimann, SM; Kuessner, D; Posthumus, J, 2017)	1.45
"Isavuconazole (BAL4815) is a promising novel broad-spectrum triazole in late-stage clinical development that has proven to be active in vitro against Aspergillus, Candida and Cryptococcus neoformans, the most common agents of IFIs."	( Isavuconazole: a new and promising antifungal triazole for the treatment of invasive fungal infections. Bouza, E; Guinea, J, 2008)	2.51
"Isavuconazole is a welcome addition to the growing antifungal armamentarium with potent in vitro activity against emerging yeast pathogens. "	( In vitro activity of isavuconazole against Trichosporon, Rhodotorula, Geotrichum, Saccharomyces and Pichia species. Fothergill, A; Patterson, TF; Sutton, DA; Thompson, GR; Wiederhold, NP, 2009)	2.11
"Isavuconazole is a novel, water soluble, broad-spectrum azole in clinical development for the treatment of invasive aspergillosis and candidiasis."	( In vitro antifungal activity of isavuconazole against 345 mucorales isolates collected at study centers in eight countries. Ghannoum, MA; González, GM; Guinea, J; Heep, M; Lass-Flörl, C; Verweij, PE; Warn, P; Wiedrhold, NP, 2009)	1.36
"Isavuconazole is a promising new antifungal drug with favorable pharmacokinetic properties and excellent activity against a number of fungi. "	( Effect of mild and moderate liver disease on the pharmacokinetics of isavuconazole after intravenous and oral administration of a single dose of the prodrug BAL8557. Edwards, DJ; Heep, M; Peterfaí, E; Roos, B; Schmitt-Hoffmann, A; Spickermann, J; Stoeckel, K, 2009)	2.03
"Isavuconazole is a new triazole currently undergoing phase III clinical trials. "	( Isavuconazole: a comprehensive review of spectrum of activity of a new triazole. Thompson, GR; Wiederhold, NP, 2010)	3.25
"Isavuconazole is a novel second-generation triazole with broad-spectrum antifungal activity, and a favorable pharmacokinetic-pharmacodynamic profile."	( Evaluation of the pharmacokinetics and clinical utility of isavuconazole for treatment of invasive fungal infections. Hope, W; Livermore, J, 2012)	1.34

Excerpt	Reference	Relevance
"Isavuconazole has a favorable pharmacokinetic and safety profile compared to other azole antifungal agents, but its high protein binding and lipophilicity raise concerns about drug sequestration in the VV-ECMO circuit."	( Decreased isavuconazole trough concentrations in the treatment of invasive aspergillosis in an adult patient receiving extracorporeal membrane oxygenation support. Kludjian, G; Miller, M; Mohrien, K; Morita, K, 2022)	1.85
"Isavuconazole (ISA) has a similar broad spectrum of activity to PCZ; however, real-world data regarding the tolerability of ISA after PCZ toxicity are lacking."	( Tolerability of isavuconazole after posaconazole toxicity in leukaemia patients. DiPippo, AJ; Kontoyiannis, DP; Rausch, CR, 2019)	1.58
"Isavuconazole has a broad spectrum of activity and favorable pharmacokinetic properties, providing an advantage over other currently available broad-spectrum azole antifungals and a clinically useful alternative to voriconazole for the treatment of invasive aspergillosis. "	( Isavuconazole: A New Option for the Management of Invasive Fungal Infections. Carver, PL; Pettit, NN, 2015)	3.3

Excerpt	Reference	Relevance
"Isavuconazole displays broad anti-mould activity. "	( Revision of EUCAST breakpoints: consequences for susceptibility of contemporary Danish mould isolates to isavuconazole and comparators. Arendrup, MC; Guinea, J; Hare, RK; Jørgensen, KM; Meletiadis, J, 2020)	2.21

Excerpt	Reference	Relevance
"Isavuconazole treatment was initiated with the standard maintenance dose of 200 mg daily."	( Successful and Safe Real-Time TDM-Guided Treatment of Invasive Pulmonary and Cerebral Aspergillosis Using Low-Dose Isavuconazole in a Patient with Primary Biliary Cirrhosis: Grand Round/A Case Study. Cojutti, PG; Giannella, M; Pea, F; Rinaldi, M; Viale, P, 2023)	1.84
"Isavuconazole-treated subjects received 372 mg of isavuconazonium sulphate (corresponding to 200 mg of isavuconazole) three times daily for 2 days, then once daily. "	( Variability and exposure-response relationships of isavuconazole plasma concentrations in the Phase 3 SECURE trial of patients with invasive mould diseases. Andes, D; Engelhardt, M; Groll, AH; Kaindl, T; Larger, P; Saulay, M, 2019)	2.21
"Treatment with isavuconazole (orally), micafungin (intraperitoneally), a combination of both or LAmB (intravenously) was compared, with survival and tissue fungal burden serving as primary and secondary endpoints, respectively."	( Monotherapy or combination therapy of isavuconazole and micafungin for treating murine mucormycosis. Alqarihi, A; Azie, N; Edwards, JE; Gebremariam, T; Ibrahim, AS; Uppuluri, P; Wiederhold, NP, 2017)	1.07

Excerpt	Reference	Relevance
" All doses were well tolerated, and no severe or serious adverse events occurred."	( Single-ascending-dose pharmacokinetics and safety of the novel broad-spectrum antifungal triazole BAL4815 after intravenous infusions (50, 100, and 200 milligrams) and oral administrations (100, 200, and 400 milligrams) of its prodrug, BAL8557, in healthy Beglinger, C; Brown, T; Heep, M; Roehrle, M; Roos, B; Schleimer, M; Schmitt-Hoffmann, A; Weidekamm, E, 2006)	0.33
" All adverse events reported were mild or moderate, except one severe rhinitis event which was not related to trial medication."	( Multiple-dose pharmacokinetics and safety of the new antifungal triazole BAL4815 after intravenous infusion and oral administration of its prodrug, BAL8557, in healthy volunteers. Brown, T; Heep, M; Maares, J; Roehrle, M; Roos, B; Schmitt-Hoffmann, A; Spickerman, J; Weidekamm, E, 2006)	0.33
" The frequency of adverse events was similar in arm A (n = 22; 55%), arm B (n = 18; 45%), and arm D (n = 22; 58%), but higher in arm C (n = 29; 71%)."	( A phase 2, randomized, double-blind, multicenter trial to evaluate the safety and efficacy of three dosing regimens of isavuconazole compared with fluconazole in patients with uncomplicated esophageal candidiasis. Azie, N; Ghannoum, M; Schmitt-Hoffmann, AH; Viljoen, J, 2015)	0.63
" The adverse events in five patients in the low-dose cohort and in eight patients in the high-dose cohort were considered to be drug related."	( Safety and pharmacokinetics of isavuconazole as antifungal prophylaxis in acute myeloid leukemia patients with neutropenia: results of a phase 2, dose escalation study. Böhme, A; Cornely, OA; Schmitt-Hoffmann, A; Ullmann, AJ, 2015)	0.7
" Improvement in the management of IFDs have been achieved with the availability of new effective and safe antifungal drugs, however, many of these newer treatments have some limitations in their variable toxicity and unique predisposition for pharmacokinetic drug-drug interactions."	( An update on the safety and interactions of antifungal drugs in stem cell transplant recipients. Girmenia, C; Iori, AP, 2017)	0.46
" All of these can cause significant adverse drug reactions."	( Isavuconazole and voriconazole for the treatment of chronic pulmonary aspergillosis: A retrospective comparison of rates of adverse events. Bongomin, F; Felton, T; Maguire, N; Moore, CB; Rautemaa-Richardson, R, 2019)	1.96
" Adverse events were seen in 18 of 21 (86%) the patients in the voriconazole group and 12 of 20 (60%) in the isavuconazole group (P = 0."	( Isavuconazole and voriconazole for the treatment of chronic pulmonary aspergillosis: A retrospective comparison of rates of adverse events. Bongomin, F; Felton, T; Maguire, N; Moore, CB; Rautemaa-Richardson, R, 2019)	2.17
"Compared with isavuconazole, adverse events were significantly higher in CPA patients commenced on voriconazole."	( Isavuconazole and voriconazole for the treatment of chronic pulmonary aspergillosis: A retrospective comparison of rates of adverse events. Bongomin, F; Felton, T; Maguire, N; Moore, CB; Rautemaa-Richardson, R, 2019)	2.32
"ISA is safe in pediatric patients for the treatment of IFI."	( Safety of Isavuconazonium Sulfate in Pediatrics Patients With Hematologic Malignancies and Hematopoietic Cell Transplantation With Invasive Fungal Infections: A Real World Experience. Chen, J; Dadwal, S; Karras, NA; Pawlowska, A; Rosenthal, J; Ross, JA; Sun, W; Tegtmeier, B; Yamada, C; Zaia, J, 2020)	0.56
"Voriconazole is frequently discontinued prematurely as primary antifungal prophylaxis (AFP) in allogeneic hematopoietic cell transplant (HCT) recipients due to adverse events."	( Efficacy and safety of isavuconazole compared with voriconazole as primary antifungal prophylaxis in allogeneic hematopoietic cell transplant recipients. Bogler, Y; Lee, YJ; Neofytos, D; Papanicolaou, GA; Perales, MA; Seo, SK; Shaffer, B; Stern, A; Su, Y, 2021)	0.93
" Antifungal management is challenging due to diagnostic delay, adverse drug reactions, drug-drug interactions, narrow therapeutic window, and the emergence of resistance."	( Efficacy and safety of Isavuconazole for the treatment of invasive Chandrasekar, PH; Sivasubramanian, G, 2022)	1.03
" It offers several advantages over other antifungal agents, including having a better adverse event profile with respect to hepatotoxicity, neuro-visual toxicity, QTc prolongation, as well as a stable pharmacokinetic profile obviating the need for therapeutic drug monitoring."	( Efficacy and safety of Isavuconazole for the treatment of invasive Chandrasekar, PH; Sivasubramanian, G, 2022)	1.03
" Mild gamma-glutamyltransferase elevation was the most frequent adverse event (34%)."	( Safety and Effectiveness of Isavuconazole Treatment for Fungal Infections in Solid Organ Transplant Recipients (ISASOT Study). Berastegui, C; Bravo, C; Campany-Herrero, D; Castells, L; Deu, M; Gavaldà, J; Len, O; Los-Arcos, I; Márquez-Algaba, E; Martín-Gómez, MT; Monforte, A; Moreso, F; Nuvials, X; Sacanell, J; Sempere, A, 2022)	1.02
" There were no serious adverse events, and all reported treatment-emergent adverse events were of mild intensity."	( Pharmacokinetics, Safety, and Tolerability of Single and Multiple Doses of Isavuconazonium Sulfate in Healthy Adult Japanese Subjects. Kumagai, Y; Ose, A; Shirae, S, 2022)	0.72
" In the safety evaluation, the incidence of adverse events in participants with chronic pulmonary aspergillosis was similar in both groups."	( Efficacy and safety of isavuconazole against deep-seated mycoses: A phase 3, randomized, open-label study in Japan. Akashi, K; Izumikawa, K; Kakeya, H; Kamei, K; Kanda, Y; Kimura, SI; Kishida, M; Kohno, S; Matsuda, M; Miyazaki, T; Miyazaki, Y; Mukae, H; Niki, Y; Ogawa, K; Okada, F; Suzuki, J; Takazono, T; Taniguchi, S; Tateda, K; Yoshida, M, 2023)	1.22
" Safety outcomes included the rates of treatment-emergent adverse events and premature isavuconazole discontinuation."	( Isavuconazole for the Treatment of Invasive Mold Disease in Solid Organ Transplant Recipients: A Multicenter Study on Efficacy and Safety in Real-life Clinical Practice. Aguado, JM; Bodro, M; Carratalà, J; Cordero, E; Fariñas, MDC; Fernández-Ruiz, M; Fortún, J; Goikoetxea, J; Gutiérrez Martín, I; Illaro, A; López-Viñau, T; Moreno, A; Muñoz, P; Ramos-Martínez, A; Rodriguez-Álvarez, R; Ruiz-Ruigómez, M; Sabé, N; Salto-Alejandre, S; Valerio, M; Vidal, E, 2023)	2.58
" At least 1 treatment-emergent adverse event occurred in 17."	( Isavuconazole for the Treatment of Invasive Mold Disease in Solid Organ Transplant Recipients: A Multicenter Study on Efficacy and Safety in Real-life Clinical Practice. Aguado, JM; Bodro, M; Carratalà, J; Cordero, E; Fariñas, MDC; Fernández-Ruiz, M; Fortún, J; Goikoetxea, J; Gutiérrez Martín, I; Illaro, A; López-Viñau, T; Moreno, A; Muñoz, P; Ramos-Martínez, A; Rodriguez-Álvarez, R; Ruiz-Ruigómez, M; Sabé, N; Salto-Alejandre, S; Valerio, M; Vidal, E, 2023)	2.35
"Isavuconazole is a safe therapeutic option for IMD in SOT recipients, with efficacy comparable to other patient groups."	( Isavuconazole for the Treatment of Invasive Mold Disease in Solid Organ Transplant Recipients: A Multicenter Study on Efficacy and Safety in Real-life Clinical Practice. Aguado, JM; Bodro, M; Carratalà, J; Cordero, E; Fariñas, MDC; Fernández-Ruiz, M; Fortún, J; Goikoetxea, J; Gutiérrez Martín, I; Illaro, A; López-Viñau, T; Moreno, A; Muñoz, P; Ramos-Martínez, A; Rodriguez-Álvarez, R; Ruiz-Ruigómez, M; Sabé, N; Salto-Alejandre, S; Valerio, M; Vidal, E, 2023)	3.8
"TDM-guided clinical pharmacological advice was essential for the successful and safe management of isavuconazole treatment in this patient with moderate liver dysfunction."	( Successful and Safe Real-Time TDM-Guided Treatment of Invasive Pulmonary and Cerebral Aspergillosis Using Low-Dose Isavuconazole in a Patient with Primary Biliary Cirrhosis: Grand Round/A Case Study. Cojutti, PG; Giannella, M; Pea, F; Rinaldi, M; Viale, P, 2023)	1.34
" Adverse events (AEs); all-cause mortality; and overall, clinical, mycological, and radiological response were assessed."	( Post-hoc analysis of the safety and efficacy of isavuconazole in older patients with invasive fungal disease from the VITAL and SECURE studies. Aram, JA; Engelhardt, M; Hamed, K; Huang, JJ; Kovanda, LL; Yan, J, 2023)	1.17
" The discontinuation rate was defined as the percentage of therapy discontinuations due to adverse events."	( A systematic review and meta-analysis of efficacy and safety of isavuconazole for the treatment and prophylaxis of invasive fungal infections. Asai, N; Hagihara, M; Hirai, J; Iwamoto, T; Kato, H; Mikamo, H; Mori, N; Umemura, T; Yamagishi, Y, 2023)	1.15
"Our meta-analysis revealed that isavuconazole was not inferior to other antifungal agents for the treatment and prophylaxis of IFIs, with substantially fewer drug-associated adverse events and discontinuations."	( A systematic review and meta-analysis of efficacy and safety of isavuconazole for the treatment and prophylaxis of invasive fungal infections. Asai, N; Hagihara, M; Hirai, J; Iwamoto, T; Kato, H; Mikamo, H; Mori, N; Umemura, T; Yamagishi, Y, 2023)	1.43

Excerpt	Reference	Relevance
" AUC values reflected a fourfold to fivefold accumulation of active drug in plasma during once-daily dosing, which is in line with the long elimination half-life of BAL4815 determined after the last administration (mean, 84."	( Multiple-dose pharmacokinetics and safety of the new antifungal triazole BAL4815 after intravenous infusion and oral administration of its prodrug, BAL8557, in healthy volunteers. Brown, T; Heep, M; Maares, J; Roehrle, M; Roos, B; Schmitt-Hoffmann, A; Spickerman, J; Weidekamm, E, 2006)	0.33
" The pharmacodynamic parameter that optimally links drug exposure with the antifungal effect was determined using dose fractionation studies."	( Pharmacokinetics and pharmacodynamics of a novel triazole, isavuconazole: mathematical modeling, importance of tissue concentrations, and impact of immune status on antifungal effect. Denning, DW; Hope, WW; Majithiya, J; Parmar, A; Sharp, A; Warn, PA, 2009)	0.6
"Isavuconazole is a promising new antifungal drug with favorable pharmacokinetic properties and excellent activity against a number of fungi."	( Effect of mild and moderate liver disease on the pharmacokinetics of isavuconazole after intravenous and oral administration of a single dose of the prodrug BAL8557. Edwards, DJ; Heep, M; Peterfaí, E; Roos, B; Schmitt-Hoffmann, A; Spickermann, J; Stoeckel, K, 2009)	2.03
"Isavuconazole has the potential to become an important agent for the treatment of invasive fungal infections, principally because of its relatively broad and potent in vitro antifungal activity, and its favorable pharmacokinetic profile."	( Evaluation of the pharmacokinetics and clinical utility of isavuconazole for treatment of invasive fungal infections. Hope, W; Livermore, J, 2012)	2.06
" They have consistently shown that the pharmacodynamic index most closely correlated with efficacy is the ratio of the 24-h area under the concentration-time curve (AUC) to the MIC, and a target 24-h free-drug AUC/MIC ratio near 25 is associated with 50% of maximal microbiologic efficacy."	( Isavuconazole pharmacodynamic target determination for Candida species in an in vivo murine disseminated candidiasis model. Andes, DR; Diekema, D; Lepak, AJ; Marchillo, K; VanHecker, J, 2013)	1.83
" One strategy used to optimize outcomes is antifungal pharmacodynamic (PD) examination."	( Isavuconazole (BAL4815) pharmacodynamic target determination in an in vivo murine model of invasive pulmonary aspergillosis against wild-type and cyp51 mutant isolates of Aspergillus fumigatus. Andes, DR; Lepak, AJ; Marchillo, K; Vanhecker, J, 2013)	1.83
" Although previously available second-generation triazole antifungals have significantly expanded the spectrum of the triazole antifungal class, these agents are laden with shortcomings in their safety profiles as well as formulation and pharmacokinetic challenges."	( Isavuconazole: Pharmacology, Pharmacodynamics, and Current Clinical Experience with a New Triazole Antifungal Agent. Marx, KR; Nishimoto, AT; Rogers, PD; Rybak, JM, 2015)	1.86
" Bridging to humans using population pharmacokinetic (PK) data from a clinical trial in invasive aspergillosis was performed using Monte Carlo simulations."	( Pharmacodynamics of isavuconazole in experimental invasive pulmonary aspergillosis: implications for clinical breakpoints. Bonate, P; Desai, A; Hope, WW; Kovanda, LL; Petraitiene, R; Petraitis, V; Walsh, TJ, 2016)	0.76
" A population pharmacokinetic (PPK) model was constructed using nonparametric estimation to compare the pharmacokinetic (PK) behaviors of isavuconazole in patients treated in the phase 3 VITAL open-label clinical trial, which evaluated the efficacy and safety of the drug for treatment of renally impaired IA patients and patients with invasive fungal disease (IFD) caused by emerging molds, yeasts, and dimorphic fungi."	( Isavuconazole Population Pharmacokinetic Analysis Using Nonparametric Estimation in Patients with Invasive Fungal Disease (Results from the VITAL Study). Akhtar, S; Bonate, P; Desai, AV; Hope, WW; Kovanda, LL; Lu, Q; Townsend, RW, 2016)	2.08
"This report summarizes phase 1 studies that evaluated pharmacokinetic interactions between the novel triazole antifungal agent isavuconazole and the immunosuppressants cyclosporine, mycophenolic acid, prednisolone, sirolimus, and tacrolimus in healthy adults."	( Pharmacokinetic Assessment of Drug-Drug Interactions of Isavuconazole With the Immunosuppressants Cyclosporine, Mycophenolic Acid, Prednisolone, Sirolimus, and Tacrolimus in Healthy Adults. Akhtar, S; Desai, A; Groll, AH; Han, D; Howieson, C; Kato, K; Kowalski, D; Lademacher, C; Lewis, W; Mandarino, D; Pearlman, H; Townsend, R; Yamazaki, T, 2017)	0.91
"This phase 1 trial evaluated pharmacokinetic and pharmacodynamic interactions between the novel triazole antifungal agent isavuconazole and warfarin in healthy adults."	( Pharmacokinetic and Pharmacodynamic Evaluation of the Drug-Drug Interaction Between Isavuconazole and Warfarin in Healthy Subjects. Akhtar, S; Desai, A; Dietz, AJ; Kowalski, D; Lademacher, C; Pearlman, H; Townsend, R; Yamazaki, T, 2017)	0.89
" The objective of this analysis was to develop a population pharmacokinetic (PPK) model to identify covariates that affect isavuconazole pharmacokinetics and to determine the probability of target attainment (PTA) for invasive aspergillosis patients."	( Population Pharmacokinetics of Isavuconazole from Phase 1 and Phase 3 (SECURE) Trials in Adults and Target Attainment in Patients with Invasive Infections Due to Aspergillus and Other Filamentous Fungi. Bonate, PL; Desai, A; Kovanda, L; Kowalski, D; Lu, Q; Townsend, R, 2016)	0.93
"Therapeutic drug monitoring (TDM) may be required to achieve optimal clinical outcomes in the setting of significant pharmacokinetic variability, a situation that applies to a number of anti-mould therapies."	( Therapeutic drug monitoring for invasive mould infections and disease: pharmacokinetic and pharmacodynamic considerations. Hope, WW; Stott, KE, 2017)	0.46
" This review aims to summarize and evaluate the published literature reporting clinical pharmacokinetic and pharmacodynamic outcome data of isavuconazole in humans."	( A Review of the Clinical Pharmacokinetics and Pharmacodynamics of Isavuconazole. Wilby, KJ, 2018)	0.92
" Data regarding the pharmacokinetic profile of isavuconazole in patients with CF undergoing lung transplantation are currently not available."	( Isavuconazole pharmacokinetics in a patient with cystic fibrosis following bilateral orthotopic lung transplantation. Kabulski, GM; MacVane, SH, 2018)	2.18
" Monte Carlo simulations were conducted using pharmacokinetic (PK) parameters and pharmacodynamics (PD) data to determine the probabilities of target attainment and cumulative fractions of response in terms of area under the concentration curve/minimum inhibition concentration (AUC/MIC) targets of isavuconazole."	( Pharmacokinetic/Pharmacodynamic Analysis of Isavuconazole Against Aspergillus spp. and Candida spp. in Healthy Subjects and Patients With Hepatic or Renal Impairment by Monte Carlo Simulation. Ding, H; Fang, L; Huang, P; Sun, J; Tong, Y; Xu, G; Zhang, Y; Zheng, X; Zhu, L, 2018)	0.92
" However, VCZ and PCZ are liable for drug-drug interactions and show a pharmacokinetic variability that requires therapeutic drug monitoring (TDM)."	( Isavuconazole: Case Report and Pharmacokinetic Considerations. Girmenia, C; Goffredo, BM; Marchesi, F; Mengarelli, A; Menna, P; Minotti, G; Romano, A; Salvatorelli, E, 2018)	1.92
" Pharmacokinetic (PK) samples were collected predose through day 21."	( Pharmacokinetics and Bioequivalence of Isavuconazole Administered as Isavuconazonium Sulfate Intravenous Solution via Nasogastric Tube or Orally in Healthy Subjects. Desai, A; Goldwater, R; Helmick, M; Heo, N; Martin, N; Moy, S; Stanhope, S, 2021)	0.89
"8 hours after PO administration with an elimination rate half-life of 66."	( Pharmacokinetics of isavuconazole in healthy cats after oral and intravenous administration. Dear, JD; Wittenburg, LA; Woerde, DJ, 2022)	1.04
"Maximum a posteriori Bayesian estimation (MAP-BE) based on a limited sampling strategy and a population pharmacokinetic (POPPK) model is used to estimate individual pharmacokinetic parameters."	( A Hybrid Algorithm Combining Population Pharmacokinetic and Machine Learning for Isavuconazole Exposure Prediction. Destere, A; Drici, MD; Labriffe, M; Marquet, P; Woillard, JB, 2023)	1.14
" This study aims to investigate the potential pharmacokinetic interactions between lenvatinib and various azoles (ketoconazole, voriconazole, isavuconazole and posaconazole) when orally administered to rats."	( Evaluation of the inhibitory effect of azoles on pharmacokinetics of lenvatinib in rats both in vivo and in vitro by UPLC-MS/MS. Geng, P; Han, A; Lu, Z; Song, X; Wang, S; Wang, Y; Wu, Q; Xia, M; Zhou, Q; Zhou, Y, 2023)	1.11
" Total and unbound isavuconazole pharmacokinetics were analysed by means of population pharmacokinetic modelling using NONMEM."	( Population Pharmacokinetics of Total and Unbound Isavuconazole in Critically Ill Patients: Implications for Adaptive Dosing Strategies. Brüggemann, RJM; Debaveye, Y; Jansen, AME; Mertens, B; Schouten, J; Spriet, I; Ter Heine, R; Verweij, PE; Wauters, J, 2023)	1.49
" This highly variable protein binding asks for re-evaluation of current pharmacokinetic and pharmacodynamic targets for isavuconazole."	( High Variability in Isavuconazole Unbound Fraction in Clinical Practice: A Call to Reconsider Pharmacokinetic/Pharmacodynamic Targets and Breakpoints. Brüggemann, RJM; Jansen, AME; Ter Heine, R; Verweij, PE, 2023)	1.44
" At least one pharmacokinetic curve was assessed."	( Pharmacokinetic investigations of isavuconazole in paediatric cancer patients show reduced exposure of isavuconazole after opening capsules for administration via a nasogastric tube. Brüggemann, RJM; Bury, D; Muilwijk, EW; Ter Heine, R; Tissing, WJE; van der Elst, KCM; Wolfs, TFW, 2023)	1.19

Excerpt	Reference	Relevance
"A paucity of data currently exists regarding drug-drug interaction (DDI) with tacrolimus and isavuconazole coadministration."	( Drug-Drug Interaction Between Isavuconazole and Tacrolimus: Is Empiric Dose Adjustment Necessary? Alexander, MD; Armistead, PM; Daniels, LM; Kufel, WD; Ptachcinski, JR; Shaw, JR, 2020)	1.07

Excerpt	Reference	Relevance
" Based on the exposure data, oral bioavailability of BAL4815 is assumed to be very high."	( Single-ascending-dose pharmacokinetics and safety of the novel broad-spectrum antifungal triazole BAL4815 after intravenous infusions (50, 100, and 200 milligrams) and oral administrations (100, 200, and 400 milligrams) of its prodrug, BAL8557, in healthy Beglinger, C; Brown, T; Heep, M; Roehrle, M; Roos, B; Schleimer, M; Schmitt-Hoffmann, A; Weidekamm, E, 2006)	0.33
" Based on AUC values after oral and intravenous administration, an excellent oral bioavailability can be predicted for BAL4815."	( Multiple-dose pharmacokinetics and safety of the new antifungal triazole BAL4815 after intravenous infusion and oral administration of its prodrug, BAL8557, in healthy volunteers. Brown, T; Heep, M; Maares, J; Roehrle, M; Roos, B; Schmitt-Hoffmann, A; Spickerman, J; Weidekamm, E, 2006)	0.33
" Reduced toxicity, enhancement of bioavailability and counteraction of resistance are features desired by clinicians."	( Newer antifungal agents. Türel, O, 2011)	0.37
" Characteristics include linear dose-proportional pharmacokinetics, intravenous and oral formulations allowing therapeutic streamlining, once daily dosing, absence of nephrotoxic solubilizing agents and excellent oral bioavailability independent of prandial status and gastric acidity."	( Isavuconazole: a new extended spectrum triazole for invasive mold diseases. Ananda-Rajah, MR; Kontoyiannis, D, 2015)	1.86
" Advantages of this triazole include the availability of a water-soluble intravenous formulation, excellent bioavailability of the oral formulation, and predictable pharmacokinetics in adults."	( Isavuconazole: A New Broad-Spectrum Triazole Antifungal Agent. Kauffman, CA; Miceli, MH, 2015)	1.86
" These characteristics, in an agent available in both a highly bioavailable oral and a β-cyclodextrin-free intravenous formulation, will likely make isavuconazole a welcome addition to the triazole class of antifungals."	( Isavuconazole: Pharmacology, Pharmacodynamics, and Current Clinical Experience with a New Triazole Antifungal Agent. Marx, KR; Nishimoto, AT; Rogers, PD; Rybak, JM, 2015)	2.06
"Two openlabel, single-dose, randomized crossover studies and one open-label, multiple-dose, parallel group study in healthy volunteers were conducted with the prodrug, isavuconazonium sulfate, to determine absolute bioavailability of the active triazole, isavuconazole (EudraCT 2007-004949-15; n = 14), and the effect of food (EudraCT 2007- 004940-63; n = 26), and pH (NCT02128893; n = 24) on the absorption of isavuconazole."	( Isavuconazole absorption following oral administration in healthy subjects is comparable to intravenous dosing, and is not affected by food, or drugs that alter stomach pH. Desai, A; Kowalski, D; Pearlman, H; Schmitt-Hoffmann, A; Townsend, R; Yamazaki, T, 2016)	2.06
" Mucositis was reported by site investigators and its impact on oral bioavailability was assessed."	( Impact of Mucositis on Absorption and Systemic Drug Exposure of Isavuconazole. Desai, AV; Engelhardt, M; Hope, WW; Kovanda, LL; Lademacher, C; Lu, Q; Maertens, J; Marty, FM, 2017)	0.69
" The most relevant pharmacokinetics features are water-solubility of the prodrug, rapid cleavage of the prodrug into active moiety and cleavage product by plasmatic esterases, high oral bioavailability of isavuconazole with an extensive penetration into most tissues and a good safety profile even in case of renal impairment."	( Isavuconazole: A new broad-spectrum azole. Part 2: pharmacokinetics and clinical activity. Denis, J; Herbrecht, R; Ledoux, MP; Nivoix, Y, 2018)	2.11
"The ATP-binding cassette transporter P-glycoprotein (P-gp) is known to limit both brain penetration and oral bioavailability of many chemotherapy drugs."	( A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein. Ambudkar, SV; Brimacombe, KR; Chen, L; Gottesman, MM; Guha, R; Hall, MD; Klumpp-Thomas, C; Lee, OW; Lee, TD; Lusvarghi, S; Robey, RW; Shen, M; Tebase, BG, 2019)	0.51
" Oral bioavailability was estimated to be approximately 88%."	( Pharmacokinetics of isavuconazole in healthy cats after oral and intravenous administration. Dear, JD; Wittenburg, LA; Woerde, DJ, 2022)	1.04
" The absolute bioavailability of isavuconazole was 41."	( Pharmacokinetic investigations of isavuconazole in paediatric cancer patients show reduced exposure of isavuconazole after opening capsules for administration via a nasogastric tube. Brüggemann, RJM; Bury, D; Muilwijk, EW; Ter Heine, R; Tissing, WJE; van der Elst, KCM; Wolfs, TFW, 2023)	1.47
"This study revealed low bioavailability after nasogastric tube administration with opened capsules."	( Pharmacokinetic investigations of isavuconazole in paediatric cancer patients show reduced exposure of isavuconazole after opening capsules for administration via a nasogastric tube. Brüggemann, RJM; Bury, D; Muilwijk, EW; Ter Heine, R; Tissing, WJE; van der Elst, KCM; Wolfs, TFW, 2023)	1.19

Excerpt	Relevance	Reference
" Once-daily oral dosing of 50- or 100-mg equivalents of BAL8557 were recently demonstrated to be efficacious in a phase 2 study conducted with patients with esophageal candidiasis."	( Multiple-dose pharmacokinetics and safety of the new antifungal triazole BAL4815 after intravenous infusion and oral administration of its prodrug, BAL8557, in healthy volunteers. Brown, T; Heep, M; Maares, J; Roehrle, M; Roos, B; Schmitt-Hoffmann, A; Spickerman, J; Weidekamm, E, 2006)	0.33
"The aim of this study was to assess the dose-response of isavuconazole, voriconazole and fluconazole in disseminated Candida tropicalis and Candida krusei infections."	( Efficacy of isavuconazole, voriconazole and fluconazole in temporarily neutropenic murine models of disseminated Candida tropicalis and Candida krusei. Denning, DW; Majithiya, J; Parmar, A; Sharp, A; Warn, PA, 2009)	0.98
" This phase 2 trial compared the efficacy and safety of three oral dosing regimens of isavuconazole with an oral fluconazole regimen in the primary treatment of uncomplicated esophageal candidiasis."	( A phase 2, randomized, double-blind, multicenter trial to evaluate the safety and efficacy of three dosing regimens of isavuconazole compared with fluconazole in patients with uncomplicated esophageal candidiasis. Azie, N; Ghannoum, M; Schmitt-Hoffmann, AH; Viljoen, J, 2015)	0.85
" The patients in the low-dose cohort (n = 11) received isavuconazole loading doses on day 1 (400/200/200 mg, 6 h apart) and day 2 (200/200 mg, 12 h apart), followed by once-daily maintenance dosing (200 mg) on days 3 to 28."	( Safety and pharmacokinetics of isavuconazole as antifungal prophylaxis in acute myeloid leukemia patients with neutropenia: results of a phase 2, dose escalation study. Böhme, A; Cornely, OA; Schmitt-Hoffmann, A; Ullmann, AJ, 2015)	0.95
" Based on currently available data, some antifungals should be dosed based on total body weight (i."	( Dosing of antifungal agents in obese people. Hall, RG; Payne, KD, 2016)	0.43
" It is available in both oral and intravenous formulations for once-a-day dosing and has favorable safety profile and drug interaction potential in comparison to voriconazole."	( Isavuconazonium sulfate for the treatment of fungal infection. Temesgen, Z; Walker, RC; Zeuli, JD, 2016)	0.43
" Simulations were performed to describe the MICs covered by the clinical dosing regimen."	( Isavuconazole Population Pharmacokinetic Analysis Using Nonparametric Estimation in Patients with Invasive Fungal Disease (Results from the VITAL Study). Akhtar, S; Bonate, P; Desai, AV; Hope, WW; Kovanda, LL; Lu, Q; Townsend, RW, 2016)	1.88
") for 2 days, followed by a single daily oral dose for 3 days, in the presence of steady state esomeprazole dosed orally at 40 mg/day."	( Isavuconazole absorption following oral administration in healthy subjects is comparable to intravenous dosing, and is not affected by food, or drugs that alter stomach pH. Desai, A; Kowalski, D; Pearlman, H; Schmitt-Hoffmann, A; Townsend, R; Yamazaki, T, 2016)	1.88
" The delivery of TDM as a future standard of care will require real-time measurement of drug concentrations at the bedside and algorithms for dosage adjustment."	( Therapeutic drug monitoring for invasive mould infections and disease: pharmacokinetic and pharmacodynamic considerations. Hope, WW; Stott, KE, 2017)	0.46
" Two hundred thirty-one patients who received the clinical dosing regimen and had exposure parameters were included in the analysis."	( Exposure-Response Relationships for Isavuconazole in Patients with Invasive Aspergillosis and Other Filamentous Fungi. Andes, D; Bonate, PL; Desai, AV; Hope, WW; Kovanda, LL; Kowalski, DL; Mouton, JW; Mujais, S; Townsend, RW, 2017)	0.73
" Using an in vivo estimation of the pharmacodynamic target and a previously published pharmacokinetic model, the probability of target attainment (PTA) was determined for a range of isavuconazole MICs using three dosing regimens (I, 200 mg once daily; II, 300 mg once daily; and III, 400 mg once daily)."	( Isavuconazole susceptibility of clinical Aspergillus fumigatus isolates and feasibility of isavuconazole dose escalation to treat isolates with elevated MICs. Brüggemann, RJM; Buil, JB; Meis, JF; Melchers, WJG; Mouton, JW; Verweij, PE; Wasmann, RE; Zoll, J, 2018)	2.12
" The PTA for isolates with an isavuconazole MIC of 1 mg/L was 92%-99% for 90% effective concentration (EC90) for the three dosing regimens."	( Isavuconazole susceptibility of clinical Aspergillus fumigatus isolates and feasibility of isavuconazole dose escalation to treat isolates with elevated MICs. Brüggemann, RJM; Buil, JB; Meis, JF; Melchers, WJG; Mouton, JW; Verweij, PE; Wasmann, RE; Zoll, J, 2018)	2.21
" Data from diseased patients confirmed these findings and also consistently demonstrated that regular dosing of isavuconazole results in achievement of concentrations and exposures that meet pharmacodynamic targets for therapeutic efficacy."	( A Review of the Clinical Pharmacokinetics and Pharmacodynamics of Isavuconazole. Wilby, KJ, 2018)	0.93
"The aim of this pharmacokinetic/pharmacodynamic (PK/PD) study is to evaluate the efficacy of various isavuconazole dosing regimens for healthy individuals and patients with hepatic or renal impairment against Aspergillus spp."	( Pharmacokinetic/Pharmacodynamic Analysis of Isavuconazole Against Aspergillus spp. and Candida spp. in Healthy Subjects and Patients With Hepatic or Renal Impairment by Monte Carlo Simulation. Ding, H; Fang, L; Huang, P; Sun, J; Tong, Y; Xu, G; Zhang, Y; Zheng, X; Zhu, L, 2018)	0.96
" For two of them, a drug dosage adjustment was proposed and applied by clinicians, together with a check for a new pharmacokinetic profile a few days later."	( Isavuconazole Kinetic Exploration for Clinical Practice. Concordet, D; Darnaud, L; Debard, A; Gandia, P; Godet, C; Lamoureux, F; Martins, P; Pontier, S; Venisse, N, 2018)	1.92
"We determined isavuconazole serum concentrations for 150 UK patients receiving standard isavuconazole dosing regimens, including serial therapeutic drug monitoring for several patients on prolonged therapy."	( Lessons from isavuconazole therapeutic drug monitoring at a United Kingdom Reference Center. Borman, AM; Fraser, M; Hughes, JM; Johnson, EM; Noel, AR; Oliver, D; Sunderland, J, 2020)	1.29
"Limited evidence concerning optimal azole dosing regimens currently exists for antifungal prophylaxis in hemato-oncological pediatric patients."	( Real-World Comparison of Isavuconazole and Voriconazole in Terms of the Need for Dosage Adjustments Guided by Clinical Pharmacological Advice During Primary Prophylaxis of Invasive Fungal Infections in Pediatric Patients with Hemato-Oncological Malignanci Belotti, T; Campoli, C; Cojutti, PG; Gatti, M; Masetti, R; Pea, F; Pession, A; Viale, P, 2022)	1.02
" CPAs for isavuconazole and voriconazole and the number of dosage adjustments were collected."	( Real-World Comparison of Isavuconazole and Voriconazole in Terms of the Need for Dosage Adjustments Guided by Clinical Pharmacological Advice During Primary Prophylaxis of Invasive Fungal Infections in Pediatric Patients with Hemato-Oncological Malignanci Belotti, T; Campoli, C; Cojutti, PG; Gatti, M; Masetti, R; Pea, F; Pession, A; Viale, P, 2022)	1.43
"Our findings suggest that there is limited variability in isavuconazole exposure in hemato-oncological pediatric patients receiving azole prophylaxis , resulting in a low need for CPA-guided dosage adjustments."	( Real-World Comparison of Isavuconazole and Voriconazole in Terms of the Need for Dosage Adjustments Guided by Clinical Pharmacological Advice During Primary Prophylaxis of Invasive Fungal Infections in Pediatric Patients with Hemato-Oncological Malignanci Belotti, T; Campoli, C; Cojutti, PG; Gatti, M; Masetti, R; Pea, F; Pession, A; Viale, P, 2022)	1.27
"VV-ECMO is an increasingly utilized life support therapy for patients with cardiac and/or respiratory failure, but its impact on medication dosing is poorly understood."	( Decreased isavuconazole trough concentrations in the treatment of invasive aspergillosis in an adult patient receiving extracorporeal membrane oxygenation support. Kludjian, G; Miller, M; Mohrien, K; Morita, K, 2022)	1.12
" The objectives of this analysis were to (1) develop a population PK model for Japanese patients with deep-seated mycoses and healthy subjects, and to identify significant covariates; (2) determine the probability of PK-pharmacodynamic (PK-PD) target attainment in Japanese patients by a clinical dosing regimen; and (3) evaluate the exposure-safety relationship of isavuconazole in Japanese patients."	( Population Pharmacokinetics, Exposure-Safety, and Probability of Target Attainment Analyses for Isavuconazole in Japanese Patients With Deep-Seated Mycoses. Kozaki, T; Mizuhata, J; Ose, A; Shirae, S; Tsuruya, Y, 2023)	1.3
" Once assessed, the predictive performance of the model using simulations of different dosing and fungal susceptibility scenarios were conducted."	( PK/PD modeling and simulation of the in vitro activity of the combinations of isavuconazole with echinocandins against Candida auris. Caballero, U; Eraso, E; Jauregizar, N; Quindós, G; Schmidt, S; Vozmediano, V, 2023)	1.14
" We aimed to describe the total and unbound isavuconazole pharmacokinetics and subsequently propose a dosage optimisation strategy."	( Population Pharmacokinetics of Total and Unbound Isavuconazole in Critically Ill Patients: Implications for Adaptive Dosing Strategies. Brüggemann, RJM; Debaveye, Y; Jansen, AME; Mertens, B; Schouten, J; Spriet, I; Ter Heine, R; Verweij, PE; Wauters, J, 2023)	1.43
" Blood samples were collected on eight timepoints over one dosing interval between days 3-7 of treatment and optionally on one timepoint after discontinuation."	( Population Pharmacokinetics of Total and Unbound Isavuconazole in Critically Ill Patients: Implications for Adaptive Dosing Strategies. Brüggemann, RJM; Debaveye, Y; Jansen, AME; Mertens, B; Schouten, J; Spriet, I; Ter Heine, R; Verweij, PE; Wauters, J, 2023)	1.16
" The proposed adaptive dosing strategy resulted in an increase to 62."	( Population Pharmacokinetics of Total and Unbound Isavuconazole in Critically Ill Patients: Implications for Adaptive Dosing Strategies. Brüggemann, RJM; Debaveye, Y; Jansen, AME; Mertens, B; Schouten, J; Spriet, I; Ter Heine, R; Verweij, PE; Wauters, J, 2023)	1.16
" We proposed an adaptive dosing approach to enhance early treatment optimisation in this high-risk population."	( Population Pharmacokinetics of Total and Unbound Isavuconazole in Critically Ill Patients: Implications for Adaptive Dosing Strategies. Brüggemann, RJM; Debaveye, Y; Jansen, AME; Mertens, B; Schouten, J; Spriet, I; Ter Heine, R; Verweij, PE; Wauters, J, 2023)	1.16
"Seven of 15 patients (47%) received standard isavuconazole loading dosage with 200 mg as the first dose, 3/15 (20%) received 300 mg, and 5/15 (33%) received 400 mg isavuconazole as the first dose, followed by subsequent standard dosing in all patients."	( Early attainment of isavuconazole target concentration using an increased loading dose in critically ill patients with extracorporeal membrane oxygenation. Eller, P; Grinschgl, Y; Hatzl, S; Hoenigl, M; Krause, R; Kriegl, L; Meinitzer, A; Muhr, T; Posch, F; Reisinger, A; Schilcher, G, 2023)	1.49

Role	Description
ergosterol biosynthesis inhibitor	Any compound that inhibits one or more steps in the pathway leading to the synthesis of ergosterol.
EC 1.14.13.70 (sterol 14alpha-demethylase) inhibitor	An EC 1.14.13.* (oxidoreductase acting on paired donors, incorporating 1 atom of oxygen, with NADH or NADPH as one donor) inhibitor that interferes with the action of EC 1.14.13.70 (sterol 14alpha-demethylase).
orphan drug	Any drug that has been developed specifically for treatment of a rare medical condition, the condition itself being known as an orphan disease.
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Class	Description
1,3-thiazoles
nitrile	A compound having the structure RC#N; thus a C-substituted derivative of hydrocyanic acid, HC#N. In systematic nomenclature, the suffix nitrile denotes the triply bound #N atom, not the carbon atom attached to it.
difluorobenzene	Any member of the class of fluorobenzenes containing a mono- or poly-substituted benzene ring carrying two fluorine atoms.
tertiary alcohol	A tertiary alcohol is a compound in which a hydroxy group, -OH, is attached to a saturated carbon atom which has three other carbon atoms attached to it.
triazole antifungal drug	Any triazole antifungal agent that has been used for the treatment of fungal infections in humans or animals.
conazole antifungal drug	Any conazole antifungal agent that has been used for the treatment of fungal infections in animals or humans.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein	Taxonomy	Measurement	Average (µ)	Min (ref.)	Avg (ref.)	Max (ref.)	Bioassay(s)
cytochrome P450 family 3 subfamily A polypeptide 4	Homo sapiens (human)	Potency	1.8999	0.0123	7.9835	43.2770	AID1645841
G	Vesicular stomatitis virus	Potency	6.0081	0.0123	8.9648	39.8107	AID1645842
cytochrome P450 2D6	Homo sapiens (human)	Potency	18.9991	0.0010	8.3798	61.1304	AID1645840
Interferon beta	Homo sapiens (human)	Potency	6.0081	0.0033	9.1582	39.8107	AID1645842
HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)	Potency	6.0081	0.0123	8.9648	39.8107	AID1645842
Spike glycoprotein	Severe acute respiratory syndrome-related coronavirus	Potency	31.9798	0.0096	10.5250	35.4813	AID1479145; AID1479148
Inositol hexakisphosphate kinase 1	Homo sapiens (human)	Potency	6.0081	0.0123	8.9648	39.8107	AID1645842
cytochrome P450 2C9, partial	Homo sapiens (human)	Potency	6.0081	0.0123	8.9648	39.8107	AID1645842
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Protein	Taxonomy	Measurement	Average	Min (ref.)	Avg (ref.)	Max (ref.)	Bioassay(s)
Broad substrate specificity ATP-binding cassette transporter ABCG2	Homo sapiens (human)	IC50 (µMol)	11.0000	0.0040	1.9666	10.0000	AID1873196
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Process	via Protein(s)	Taxonomy
cell surface receptor signaling pathway via JAK-STAT	Interferon beta	Homo sapiens (human)
response to exogenous dsRNA	Interferon beta	Homo sapiens (human)
B cell activation involved in immune response	Interferon beta	Homo sapiens (human)
cell surface receptor signaling pathway	Interferon beta	Homo sapiens (human)
cell surface receptor signaling pathway via JAK-STAT	Interferon beta	Homo sapiens (human)
response to virus	Interferon beta	Homo sapiens (human)
positive regulation of autophagy	Interferon beta	Homo sapiens (human)
cytokine-mediated signaling pathway	Interferon beta	Homo sapiens (human)
natural killer cell activation	Interferon beta	Homo sapiens (human)
positive regulation of peptidyl-serine phosphorylation of STAT protein	Interferon beta	Homo sapiens (human)
cellular response to interferon-beta	Interferon beta	Homo sapiens (human)
B cell proliferation	Interferon beta	Homo sapiens (human)
negative regulation of viral genome replication	Interferon beta	Homo sapiens (human)
innate immune response	Interferon beta	Homo sapiens (human)
positive regulation of innate immune response	Interferon beta	Homo sapiens (human)
regulation of MHC class I biosynthetic process	Interferon beta	Homo sapiens (human)
negative regulation of T cell differentiation	Interferon beta	Homo sapiens (human)
positive regulation of transcription by RNA polymerase II	Interferon beta	Homo sapiens (human)
defense response to virus	Interferon beta	Homo sapiens (human)
type I interferon-mediated signaling pathway	Interferon beta	Homo sapiens (human)
neuron cellular homeostasis	Interferon beta	Homo sapiens (human)
cellular response to exogenous dsRNA	Interferon beta	Homo sapiens (human)
cellular response to virus	Interferon beta	Homo sapiens (human)
negative regulation of Lewy body formation	Interferon beta	Homo sapiens (human)
negative regulation of T-helper 2 cell cytokine production	Interferon beta	Homo sapiens (human)
positive regulation of apoptotic signaling pathway	Interferon beta	Homo sapiens (human)
response to exogenous dsRNA	Interferon beta	Homo sapiens (human)
B cell differentiation	Interferon beta	Homo sapiens (human)
natural killer cell activation involved in immune response	Interferon beta	Homo sapiens (human)
adaptive immune response	Interferon beta	Homo sapiens (human)
T cell activation involved in immune response	Interferon beta	Homo sapiens (human)
humoral immune response	Interferon beta	Homo sapiens (human)
positive regulation of T cell mediated cytotoxicity	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
adaptive immune response	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
antigen processing and presentation of endogenous peptide antigen via MHC class I via ER pathway, TAP-independent	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
regulation of T cell anergy	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
defense response	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
immune response	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
detection of bacterium	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
regulation of interleukin-12 production	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
regulation of interleukin-6 production	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
protection from natural killer cell mediated cytotoxicity	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
innate immune response	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
regulation of dendritic cell differentiation	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
antigen processing and presentation of endogenous peptide antigen via MHC class Ib	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
inositol phosphate metabolic process	Inositol hexakisphosphate kinase 1	Homo sapiens (human)
phosphatidylinositol phosphate biosynthetic process	Inositol hexakisphosphate kinase 1	Homo sapiens (human)
negative regulation of cold-induced thermogenesis	Inositol hexakisphosphate kinase 1	Homo sapiens (human)
inositol phosphate biosynthetic process	Inositol hexakisphosphate kinase 1	Homo sapiens (human)
lipid transport	Broad substrate specificity ATP-binding cassette transporter ABCG2	Homo sapiens (human)
organic anion transport	Broad substrate specificity ATP-binding cassette transporter ABCG2	Homo sapiens (human)
urate transport	Broad substrate specificity ATP-binding cassette transporter ABCG2	Homo sapiens (human)
biotin transport	Broad substrate specificity ATP-binding cassette transporter ABCG2	Homo sapiens (human)
sphingolipid biosynthetic process	Broad substrate specificity ATP-binding cassette transporter ABCG2	Homo sapiens (human)
riboflavin transport	Broad substrate specificity ATP-binding cassette transporter ABCG2	Homo sapiens (human)
urate metabolic process	Broad substrate specificity ATP-binding cassette transporter ABCG2	Homo sapiens (human)
transmembrane transport	Broad substrate specificity ATP-binding cassette transporter ABCG2	Homo sapiens (human)
transepithelial transport	Broad substrate specificity ATP-binding cassette transporter ABCG2	Homo sapiens (human)
renal urate salt excretion	Broad substrate specificity ATP-binding cassette transporter ABCG2	Homo sapiens (human)
export across plasma membrane	Broad substrate specificity ATP-binding cassette transporter ABCG2	Homo sapiens (human)
transport across blood-brain barrier	Broad substrate specificity ATP-binding cassette transporter ABCG2	Homo sapiens (human)
cellular detoxification	Broad substrate specificity ATP-binding cassette transporter ABCG2	Homo sapiens (human)
xenobiotic transport across blood-brain barrier	Broad substrate specificity ATP-binding cassette transporter ABCG2	Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Process	via Protein(s)	Taxonomy
cytokine activity	Interferon beta	Homo sapiens (human)
cytokine receptor binding	Interferon beta	Homo sapiens (human)
type I interferon receptor binding	Interferon beta	Homo sapiens (human)
protein binding	Interferon beta	Homo sapiens (human)
chloramphenicol O-acetyltransferase activity	Interferon beta	Homo sapiens (human)
TAP binding	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
signaling receptor binding	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
protein binding	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
peptide antigen binding	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
TAP binding	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
protein-folding chaperone binding	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
inositol-1,3,4,5,6-pentakisphosphate kinase activity	Inositol hexakisphosphate kinase 1	Homo sapiens (human)
inositol hexakisphosphate kinase activity	Inositol hexakisphosphate kinase 1	Homo sapiens (human)
inositol heptakisphosphate kinase activity	Inositol hexakisphosphate kinase 1	Homo sapiens (human)
inositol hexakisphosphate 5-kinase activity	Inositol hexakisphosphate kinase 1	Homo sapiens (human)
protein binding	Inositol hexakisphosphate kinase 1	Homo sapiens (human)
ATP binding	Inositol hexakisphosphate kinase 1	Homo sapiens (human)
inositol hexakisphosphate 1-kinase activity	Inositol hexakisphosphate kinase 1	Homo sapiens (human)
inositol hexakisphosphate 3-kinase activity	Inositol hexakisphosphate kinase 1	Homo sapiens (human)
inositol 5-diphosphate pentakisphosphate 5-kinase activity	Inositol hexakisphosphate kinase 1	Homo sapiens (human)
inositol diphosphate tetrakisphosphate kinase activity	Inositol hexakisphosphate kinase 1	Homo sapiens (human)
protein binding	Broad substrate specificity ATP-binding cassette transporter ABCG2	Homo sapiens (human)
ATP binding	Broad substrate specificity ATP-binding cassette transporter ABCG2	Homo sapiens (human)
organic anion transmembrane transporter activity	Broad substrate specificity ATP-binding cassette transporter ABCG2	Homo sapiens (human)
ABC-type xenobiotic transporter activity	Broad substrate specificity ATP-binding cassette transporter ABCG2	Homo sapiens (human)
urate transmembrane transporter activity	Broad substrate specificity ATP-binding cassette transporter ABCG2	Homo sapiens (human)
biotin transmembrane transporter activity	Broad substrate specificity ATP-binding cassette transporter ABCG2	Homo sapiens (human)
efflux transmembrane transporter activity	Broad substrate specificity ATP-binding cassette transporter ABCG2	Homo sapiens (human)
ATP hydrolysis activity	Broad substrate specificity ATP-binding cassette transporter ABCG2	Homo sapiens (human)
riboflavin transmembrane transporter activity	Broad substrate specificity ATP-binding cassette transporter ABCG2	Homo sapiens (human)
ATPase-coupled transmembrane transporter activity	Broad substrate specificity ATP-binding cassette transporter ABCG2	Homo sapiens (human)
identical protein binding	Broad substrate specificity ATP-binding cassette transporter ABCG2	Homo sapiens (human)
protein homodimerization activity	Broad substrate specificity ATP-binding cassette transporter ABCG2	Homo sapiens (human)
xenobiotic transmembrane transporter activity	Broad substrate specificity ATP-binding cassette transporter ABCG2	Homo sapiens (human)
sphingolipid transporter activity	Broad substrate specificity ATP-binding cassette transporter ABCG2	Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Process	via Protein(s)	Taxonomy
extracellular space	Interferon beta	Homo sapiens (human)
extracellular region	Interferon beta	Homo sapiens (human)
Golgi membrane	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
endoplasmic reticulum	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
Golgi apparatus	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
plasma membrane	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
cell surface	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
ER to Golgi transport vesicle membrane	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
membrane	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
secretory granule membrane	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
phagocytic vesicle membrane	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
early endosome membrane	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
recycling endosome membrane	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
extracellular exosome	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
lumenal side of endoplasmic reticulum membrane	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
MHC class I protein complex	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
extracellular space	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
external side of plasma membrane	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
virion membrane	Spike glycoprotein	Severe acute respiratory syndrome-related coronavirus
fibrillar center	Inositol hexakisphosphate kinase 1	Homo sapiens (human)
nucleoplasm	Inositol hexakisphosphate kinase 1	Homo sapiens (human)
cytosol	Inositol hexakisphosphate kinase 1	Homo sapiens (human)
nucleus	Inositol hexakisphosphate kinase 1	Homo sapiens (human)
cytoplasm	Inositol hexakisphosphate kinase 1	Homo sapiens (human)
nucleoplasm	Broad substrate specificity ATP-binding cassette transporter ABCG2	Homo sapiens (human)
plasma membrane	Broad substrate specificity ATP-binding cassette transporter ABCG2	Homo sapiens (human)
apical plasma membrane	Broad substrate specificity ATP-binding cassette transporter ABCG2	Homo sapiens (human)
brush border membrane	Broad substrate specificity ATP-binding cassette transporter ABCG2	Homo sapiens (human)
mitochondrial membrane	Broad substrate specificity ATP-binding cassette transporter ABCG2	Homo sapiens (human)
membrane raft	Broad substrate specificity ATP-binding cassette transporter ABCG2	Homo sapiens (human)
external side of apical plasma membrane	Broad substrate specificity ATP-binding cassette transporter ABCG2	Homo sapiens (human)
plasma membrane	Broad substrate specificity ATP-binding cassette transporter ABCG2	Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (158)

Assay ID	Title	Year	Journal	Article
AID1347159	Primary screen GU Rhodamine qHTS for Zika virus inhibitors: Unlinked NS2B-NS3 protease assay	2020	Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49	Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1296008	Cytotoxic Profiling of Annotated Libraries Using Quantitative High-Throughput Screening	2020	SLAS discovery : advancing life sciences R & D, 01, Volume: 25, Issue:1	Cytotoxic Profiling of Annotated and Diverse Chemical Libraries Using Quantitative High-Throughput Screening.
AID1346986	P-glycoprotein substrates identified in KB-3-1 adenocarcinoma cell line, qHTS therapeutic library screen	2019	Molecular pharmacology, 11, Volume: 96, Issue:5	A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1347160	Primary screen NINDS Rhodamine qHTS for Zika virus inhibitors	2020	Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49	Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1346987	P-glycoprotein substrates identified in KB-8-5-11 adenocarcinoma cell line, qHTS therapeutic library screen	2019	Molecular pharmacology, 11, Volume: 96, Issue:5	A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID519513	Antifungal activity against Candida tropicalis isolates after 48 hrs by CLSI M27-A2 procedure based assay	2008	Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4	In vitro antifungal activities of isavuconazole (BAL4815), voriconazole, and fluconazole against 1,007 isolates of zygomycete, Candida, Aspergillus, Fusarium, and Scedosporium species.
AID567444	Antifungal activity against Trichosporon asahii after 48 hrs by Etest	2010	Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9	In vitro antifungal activities of isavuconazole and comparators against rare yeast pathogens.
AID567435	Antifungal activity against Trichosporon mucoides after 48 hrs by broth microdilution method	2010	Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9	In vitro antifungal activities of isavuconazole and comparators against rare yeast pathogens.
AID519491	Antifungal activity against Aspergillus fumigatus isolates after 48 hrs by CLSI M38-A procedure based assay	2008	Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4	In vitro antifungal activities of isavuconazole (BAL4815), voriconazole, and fluconazole against 1,007 isolates of zygomycete, Candida, Aspergillus, Fusarium, and Scedosporium species.
AID519517	Antifungal activity against Aspergillus flavus isolates by Etest	2008	Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4	In vitro antifungal activities of isavuconazole (BAL4815), voriconazole, and fluconazole against 1,007 isolates of zygomycete, Candida, Aspergillus, Fusarium, and Scedosporium species.
AID557631	Fungicidal activity against Rhizopus	2009	Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4	In vitro activity of Isavuconazole against Aspergillus species and zygomycetes according to the methodology of the European Committee on Antimicrobial Susceptibility Testing.
AID519528	Antifungal activity against Candida albicans isolates by Etest	2008	Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4	In vitro antifungal activities of isavuconazole (BAL4815), voriconazole, and fluconazole against 1,007 isolates of zygomycete, Candida, Aspergillus, Fusarium, and Scedosporium species.
AID567429	Antifungal activity against Dipodascus capitatus after 48 hrs by broth microdilution method	2010	Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9	In vitro antifungal activities of isavuconazole and comparators against rare yeast pathogens.
AID519516	Antifungal activity against Aspergillus fumigatus isolates by Etest	2008	Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4	In vitro antifungal activities of isavuconazole (BAL4815), voriconazole, and fluconazole against 1,007 isolates of zygomycete, Candida, Aspergillus, Fusarium, and Scedosporium species.
AID519465	Antimicrobial activity against Cryptococcus neoformans var. grubii clinical isolate by broth microdilution method	2008	Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4	In Vitro activity of the new azole isavuconazole (BAL4815) compared with six other antifungal agents against 162 Cryptococcus neoformans isolates from Cuba.
AID557627	Fungicidal activity against Aspergillus flavus	2009	Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4	In vitro activity of Isavuconazole against Aspergillus species and zygomycetes according to the methodology of the European Committee on Antimicrobial Susceptibility Testing.
AID559002	Ratio of AUC to MIC in mouse infected with Candida albicans FA/6862 at 6.74 mg/kg, sc BID	2009	Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8	Pharmacokinetics and pharmacodynamics of a novel triazole, isavuconazole: mathematical modeling, importance of tissue concentrations, and impact of immune status on antifungal effect.
AID567431	Antifungal activity against Rhodotorula mucilaginosa after 48 hrs by broth microdilution method	2010	Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9	In vitro antifungal activities of isavuconazole and comparators against rare yeast pathogens.
AID558990	Terminal half life in mouse at 1.6 to 13 mg/kg, sc	2009	Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8	Pharmacokinetics and pharmacodynamics of a novel triazole, isavuconazole: mathematical modeling, importance of tissue concentrations, and impact of immune status on antifungal effect.
AID557608	Antifungal activity against amphotericin B-resistant Aspergillus terreus by EUCAST method	2009	Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4	In vitro activity of Isavuconazole against Aspergillus species and zygomycetes according to the methodology of the European Committee on Antimicrobial Susceptibility Testing.
AID557614	Antifungal activity against Mucor by EUCAST method	2009	Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4	In vitro activity of Isavuconazole against Aspergillus species and zygomycetes according to the methodology of the European Committee on Antimicrobial Susceptibility Testing.
AID519515	Antifungal activity against Candida krusei isolates after 48 hrs by CLSI M27-A2 procedure based assay	2008	Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4	In vitro antifungal activities of isavuconazole (BAL4815), voriconazole, and fluconazole against 1,007 isolates of zygomycete, Candida, Aspergillus, Fusarium, and Scedosporium species.
AID519527	Antifungal activity against Scedosporium prolificans isolates by Etest	2008	Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4	In vitro antifungal activities of isavuconazole (BAL4815), voriconazole, and fluconazole against 1,007 isolates of zygomycete, Candida, Aspergillus, Fusarium, and Scedosporium species.
AID567434	Antifungal activity against Saccharomyces cerevisiae after 48 hrs by Etest	2010	Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9	In vitro antifungal activities of isavuconazole and comparators against rare yeast pathogens.
AID519468	Antimicrobial activity against Cryptococcus gattii by broth microdilution method	2008	Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4	In Vitro activity of the new azole isavuconazole (BAL4815) compared with six other antifungal agents against 162 Cryptococcus neoformans isolates from Cuba.
AID567445	Antifungal activity against Trichosporon mucoides assessed as percent susceptible isolates after 48 hrs by broth microdilution method	2010	Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9	In vitro antifungal activities of isavuconazole and comparators against rare yeast pathogens.
AID558995	Ratio of AUC to MIC in mouse infected with Candida albicans FA/6862 at 5.35 mg/kg, sc administered as single dose	2009	Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8	Pharmacokinetics and pharmacodynamics of a novel triazole, isavuconazole: mathematical modeling, importance of tissue concentrations, and impact of immune status on antifungal effect.
AID519535	Antifungal activity against Fusarium sp. isolates assessed as lowest compound concentration that produced complete inhibition of microbial growth after 24 hrs by CLSI M38-A procedure based assay	2008	Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4	In vitro antifungal activities of isavuconazole (BAL4815), voriconazole, and fluconazole against 1,007 isolates of zygomycete, Candida, Aspergillus, Fusarium, and Scedosporium species.
AID557633	Fungicidal activity against Cunninghamella	2009	Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4	In vitro activity of Isavuconazole against Aspergillus species and zygomycetes according to the methodology of the European Committee on Antimicrobial Susceptibility Testing.
AID557613	Antifungal activity against Rhizopus by EUCAST method	2009	Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4	In vitro activity of Isavuconazole against Aspergillus species and zygomycetes according to the methodology of the European Committee on Antimicrobial Susceptibility Testing.
AID519497	Antifungal activity against Candida albicans isolates after 48 hrs by CLSI M27-A2 procedure based assay	2008	Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4	In vitro antifungal activities of isavuconazole (BAL4815), voriconazole, and fluconazole against 1,007 isolates of zygomycete, Candida, Aspergillus, Fusarium, and Scedosporium species.
AID567440	Antifungal activity against Trichosporon jirovecii after 48 hrs by Etest	2010	Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9	In vitro antifungal activities of isavuconazole and comparators against rare yeast pathogens.
AID519498	Antifungal activity against Mucor isolates assessed as lowest compound concentration that produced complete inhibition of microbial growth after 24 hrs by CLSI M38-A procedure based assay	2008	Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4	In vitro antifungal activities of isavuconazole (BAL4815), voriconazole, and fluconazole against 1,007 isolates of zygomycete, Candida, Aspergillus, Fusarium, and Scedosporium species.
AID519500	Antifungal activity against Rhizopus isolates assessed as lowest compound concentration that produced complete inhibition of microbial growth after 24 hrs by CLSI M38-A procedure based assay	2008	Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4	In vitro antifungal activities of isavuconazole (BAL4815), voriconazole, and fluconazole against 1,007 isolates of zygomycete, Candida, Aspergillus, Fusarium, and Scedosporium species.
AID519492	Antifungal activity against Aspergillus flavus isolates after 48 hrs by CLSI M38-A procedure based assay	2008	Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4	In vitro antifungal activities of isavuconazole (BAL4815), voriconazole, and fluconazole against 1,007 isolates of zygomycete, Candida, Aspergillus, Fusarium, and Scedosporium species.
AID557617	Antifungal activity against amphotericin B-resistant Aspergillus terreus hyphae by EUCAST method	2009	Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4	In vitro activity of Isavuconazole against Aspergillus species and zygomycetes according to the methodology of the European Committee on Antimicrobial Susceptibility Testing.
AID558991	Antifungal activity against Candida albicans FA/6862 infected in mouse assessed as fungal load per gram of kidney at 1.6 to 13 mg/kg, sc measured after 29 hrs postinfection	2009	Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8	Pharmacokinetics and pharmacodynamics of a novel triazole, isavuconazole: mathematical modeling, importance of tissue concentrations, and impact of immune status on antifungal effect.
AID519504	Antifungal activity against Cunninghamella isolates assessed as lowest compound concentration that produced complete inhibition of microbial growth after 24 hrs by CLSI M38-A procedure based assay	2008	Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4	In vitro antifungal activities of isavuconazole (BAL4815), voriconazole, and fluconazole against 1,007 isolates of zygomycete, Candida, Aspergillus, Fusarium, and Scedosporium species.
AID519531	Antifungal activity against Candida tropicalis isolates by Etest	2008	Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4	In vitro antifungal activities of isavuconazole (BAL4815), voriconazole, and fluconazole against 1,007 isolates of zygomycete, Candida, Aspergillus, Fusarium, and Scedosporium species.
AID519467	Antimicrobial activity against Cryptococcus neoformans var. grubii obtained from non-AIDS patient by broth microdilution method	2008	Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4	In Vitro activity of the new azole isavuconazole (BAL4815) compared with six other antifungal agents against 162 Cryptococcus neoformans isolates from Cuba.
AID525544	Antimicrobial activity against Fonsecaea nubica isolates after 72 hrs by CLSI M38-A2 protocol method	2010	Antimicrobial agents and chemotherapy, Apr, Volume: 54, Issue:4	In vitro activities of eight antifungal drugs against 55 clinical isolates of Fonsecaea spp.
AID323595	Antifungal activity against Candida glabrata bloodstream isolates by broth microdilution method	2007	Antimicrobial agents and chemotherapy, May, Volume: 51, Issue:5	In vitro activities of isavuconazole and other antifungal agents against Candida bloodstream isolates.
AID525542	Antimicrobial activity against Fonsecaea pedrosoi isolates after 72 hrs by CLSI M38-A2 protocol method	2010	Antimicrobial agents and chemotherapy, Apr, Volume: 54, Issue:4	In vitro activities of eight antifungal drugs against 55 clinical isolates of Fonsecaea spp.
AID519512	Antifungal activity against Candida glabrata isolates after 48 hrs by CLSI M27-A2 procedure based assay	2008	Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4	In vitro antifungal activities of isavuconazole (BAL4815), voriconazole, and fluconazole against 1,007 isolates of zygomycete, Candida, Aspergillus, Fusarium, and Scedosporium species.
AID519521	Antifungal activity against Mucor isolates by Etest	2008	Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4	In vitro antifungal activities of isavuconazole (BAL4815), voriconazole, and fluconazole against 1,007 isolates of zygomycete, Candida, Aspergillus, Fusarium, and Scedosporium species.
AID557629	Fungicidal activity against Rhizomucor	2009	Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4	In vitro activity of Isavuconazole against Aspergillus species and zygomycetes according to the methodology of the European Committee on Antimicrobial Susceptibility Testing.
AID567437	Antifungal activity against Trichosporon inkin after 48 hrs by broth microdilution method	2010	Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9	In vitro antifungal activities of isavuconazole and comparators against rare yeast pathogens.
AID323594	Antifungal activity against Candida albicans bloodstream isolates by broth microdilution method	2007	Antimicrobial agents and chemotherapy, May, Volume: 51, Issue:5	In vitro activities of isavuconazole and other antifungal agents against Candida bloodstream isolates.
AID519493	Antifungal activity against Aspergillus niger isolates after 48 hrs by CLSI M38-A procedure based assay	2008	Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4	In vitro antifungal activities of isavuconazole (BAL4815), voriconazole, and fluconazole against 1,007 isolates of zygomycete, Candida, Aspergillus, Fusarium, and Scedosporium species.
AID557628	Fungicidal activity against Aspergillus niger	2009	Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4	In vitro activity of Isavuconazole against Aspergillus species and zygomycetes according to the methodology of the European Committee on Antimicrobial Susceptibility Testing.
AID519532	Antifungal activity against Candida sp. isolates by Etest	2008	Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4	In vitro antifungal activities of isavuconazole (BAL4815), voriconazole, and fluconazole against 1,007 isolates of zygomycete, Candida, Aspergillus, Fusarium, and Scedosporium species.
AID557637	Antifungal activity against Aspergillus niger by broth microdilution method	2009	Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4	In vitro activity of Isavuconazole against Aspergillus species and zygomycetes according to the methodology of the European Committee on Antimicrobial Susceptibility Testing.
AID567426	Antifungal activity against Rhodotorula mucilaginosa after 7 days by broth microdilution method	2010	Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9	In vitro antifungal activities of isavuconazole and comparators against rare yeast pathogens.
AID557626	Fungicidal activity against amphotericin B-resistant Aspergillus terreus	2009	Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4	In vitro activity of Isavuconazole against Aspergillus species and zygomycetes according to the methodology of the European Committee on Antimicrobial Susceptibility Testing.
AID567439	Antifungal activity against Trichosporon jirovecii after 48 hrs by broth microdilution method	2010	Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9	In vitro antifungal activities of isavuconazole and comparators against rare yeast pathogens.
AID519510	Antifungal activity against Scedosporium prolificans isolates assessed as lowest compound concentration that produced complete inhibition of microbial growth after 24 hrs by CLSI M38-A procedure based assay	2008	Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4	In vitro antifungal activities of isavuconazole (BAL4815), voriconazole, and fluconazole against 1,007 isolates of zygomycete, Candida, Aspergillus, Fusarium, and Scedosporium species.
AID519464	Antimicrobial activity against Cryptococcus neoformans var. grubii by broth microdilution method	2008	Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4	In Vitro activity of the new azole isavuconazole (BAL4815) compared with six other antifungal agents against 162 Cryptococcus neoformans isolates from Cuba.
AID519508	Antifungal activity against Scedosporium apiospermum isolates assessed as lowest compound concentration that produced complete inhibition of microbial growth after 24 hrs by CLSI M38-A procedure based assay	2008	Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4	In vitro antifungal activities of isavuconazole (BAL4815), voriconazole, and fluconazole against 1,007 isolates of zygomycete, Candida, Aspergillus, Fusarium, and Scedosporium species.
AID535684	Antibacterial activity against Cryptococcus gattii after 72 hrs by broth microdilution method	2009	Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1	Antifungal susceptibilities among different serotypes of Cryptococcus gattii and Cryptococcus neoformans.
AID567442	Antifungal activity against Trichosporon domesticum after 48 hrs by Etest	2010	Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9	In vitro antifungal activities of isavuconazole and comparators against rare yeast pathogens.
AID519534	Antifungal activity against Fusarium sp. isolates by Etest	2008	Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4	In vitro antifungal activities of isavuconazole (BAL4815), voriconazole, and fluconazole against 1,007 isolates of zygomycete, Candida, Aspergillus, Fusarium, and Scedosporium species.
AID567443	Antifungal activity against Trichosporon asahii after 48 hrs by broth microdilution method	2010	Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9	In vitro antifungal activities of isavuconazole and comparators against rare yeast pathogens.
AID519501	Antifungal activity against Rhizopus isolates assessed as lowest compound concentration that produced slight growth or approximately 25% of that of growth control after 24 hrs by CLSI M38-A procedure based assay	2008	Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4	In vitro antifungal activities of isavuconazole (BAL4815), voriconazole, and fluconazole against 1,007 isolates of zygomycete, Candida, Aspergillus, Fusarium, and Scedosporium species.
AID558998	Ratio of AUC to MIC in mouse infected with Candida albicans FA/6862 at 8.12 mg/kg, sc administered as single dose	2009	Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8	Pharmacokinetics and pharmacodynamics of a novel triazole, isavuconazole: mathematical modeling, importance of tissue concentrations, and impact of immune status on antifungal effect.
AID567438	Antifungal activity against Trichosporon inkin after 48 hrs by Etest	2010	Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9	In vitro antifungal activities of isavuconazole and comparators against rare yeast pathogens.
AID558987	Antifungal activity against Candida albicans FA/6862 assessed as postantifungal effect at =< 1 time MIC by CLSI M27-A2 method	2009	Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8	Pharmacokinetics and pharmacodynamics of a novel triazole, isavuconazole: mathematical modeling, importance of tissue concentrations, and impact of immune status on antifungal effect.
AID323597	Antifungal activity against Candida parapsilosis bloodstream isolates by broth microdilution method	2007	Antimicrobial agents and chemotherapy, May, Volume: 51, Issue:5	In vitro activities of isavuconazole and other antifungal agents against Candida bloodstream isolates.
AID519502	Antifungal activity against Absidia isolates assessed as lowest compound concentration that produced complete inhibition of microbial growth after 24 hrs by CLSI M38-A procedure based assay	2008	Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4	In vitro antifungal activities of isavuconazole (BAL4815), voriconazole, and fluconazole against 1,007 isolates of zygomycete, Candida, Aspergillus, Fusarium, and Scedosporium species.
AID557636	Antifungal activity against amphotericin B-resistant Aspergillus terreus by broth microdilution method	2009	Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4	In vitro activity of Isavuconazole against Aspergillus species and zygomycetes according to the methodology of the European Committee on Antimicrobial Susceptibility Testing.
AID567430	Antifungal activity against Dipodascus capitatus after 48 hrs by Etest	2010	Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9	In vitro antifungal activities of isavuconazole and comparators against rare yeast pathogens.
AID567446	Antifungal activity against Trichosporon mucoides assessed as percent susceptible/dose-dependent isolates after 48 hrs by broth microdilution method	2010	Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9	In vitro antifungal activities of isavuconazole and comparators against rare yeast pathogens.
AID557618	Antifungal activity against Aspergillus flavus hyphae by EUCAST method	2009	Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4	In vitro activity of Isavuconazole against Aspergillus species and zygomycetes according to the methodology of the European Committee on Antimicrobial Susceptibility Testing.
AID323599	Antifungal activity against Candida sp. bloodstream isolates by broth microdilution method	2007	Antimicrobial agents and chemotherapy, May, Volume: 51, Issue:5	In vitro activities of isavuconazole and other antifungal agents against Candida bloodstream isolates.
AID558986	Antifungal activity against Candida albicans FA/6862 by CLSI M27-A2 method	2009	Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8	Pharmacokinetics and pharmacodynamics of a novel triazole, isavuconazole: mathematical modeling, importance of tissue concentrations, and impact of immune status on antifungal effect.
AID557621	Antifungal activity against Absidia hyphae by EUCAST method	2009	Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4	In vitro activity of Isavuconazole against Aspergillus species and zygomycetes according to the methodology of the European Committee on Antimicrobial Susceptibility Testing.
AID519466	Antimicrobial activity against Cryptococcus neoformans var. grubii obtained from AIDS patient by broth microdilution method	2008	Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4	In Vitro activity of the new azole isavuconazole (BAL4815) compared with six other antifungal agents against 162 Cryptococcus neoformans isolates from Cuba.
AID535689	Antibacterial activity against Cryptococcus gattii serotype B after 72 hrs by broth microdilution method	2009	Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1	Antifungal susceptibilities among different serotypes of Cryptococcus gattii and Cryptococcus neoformans.
AID1817568	Antifungal activity against pan-azole resistant Aspergillus fumigatus SR47013 harbouring Cyp51A Y121F mutant assessed as inhibition of fungal growth incubated for 24 hrs by broth microdilution method	2021	Journal of medicinal chemistry, 07-22, Volume: 64, Issue:14	Identification of Thiazoyl Guanidine Derivatives as Novel Antifungal Agents Inhibiting Ergosterol Biosynthesis for Treatment of Invasive Fungal Infections.
AID519533	Antifungal activity against Candida krusei isolates by Etest	2008	Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4	In vitro antifungal activities of isavuconazole (BAL4815), voriconazole, and fluconazole against 1,007 isolates of zygomycete, Candida, Aspergillus, Fusarium, and Scedosporium species.
AID557607	Antifungal activity against Aspergillus fumigatus by EUCAST method	2009	Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4	In vitro activity of Isavuconazole against Aspergillus species and zygomycetes according to the methodology of the European Committee on Antimicrobial Susceptibility Testing.
AID535687	Antibacterial activity against Cryptococcus neoformans serotype D after 72 hrs by broth microdilution method	2009	Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1	Antifungal susceptibilities among different serotypes of Cryptococcus gattii and Cryptococcus neoformans.
AID535686	Antibacterial activity against Cryptococcus neoformans serotype A after 72 hrs by broth microdilution method	2009	Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1	Antifungal susceptibilities among different serotypes of Cryptococcus gattii and Cryptococcus neoformans.
AID519496	Antifungal activity against Candida parapsilosis isolates after 48 hrs by CLSI M27-A2 procedure based assay	2008	Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4	In vitro antifungal activities of isavuconazole (BAL4815), voriconazole, and fluconazole against 1,007 isolates of zygomycete, Candida, Aspergillus, Fusarium, and Scedosporium species.
AID519581	Antifungal activity against Aspergillus terreus isolates after 48 hrs by CLSI M38-A procedure based assay	2008	Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4	In vitro antifungal activities of isavuconazole (BAL4815), voriconazole, and fluconazole against 1,007 isolates of zygomycete, Candida, Aspergillus, Fusarium, and Scedosporium species.
AID557609	Antifungal activity against Aspergillus flavus by EUCAST method	2009	Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4	In vitro activity of Isavuconazole against Aspergillus species and zygomycetes according to the methodology of the European Committee on Antimicrobial Susceptibility Testing.
AID567436	Antifungal activity against Trichosporon mucoides after 48 hrs by Etest	2010	Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9	In vitro antifungal activities of isavuconazole and comparators against rare yeast pathogens.
AID567432	Antifungal activity against Rhodotorula mucilaginosa after 48 hrs by Etest	2010	Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9	In vitro antifungal activities of isavuconazole and comparators against rare yeast pathogens.
AID557611	Antifungal activity against Rhizomucor by EUCAST method	2009	Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4	In vitro activity of Isavuconazole against Aspergillus species and zygomycetes according to the methodology of the European Committee on Antimicrobial Susceptibility Testing.
AID519470	Antimicrobial activity against Cryptococcus albidosimilis by broth microdilution method	2008	Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4	In Vitro activity of the new azole isavuconazole (BAL4815) compared with six other antifungal agents against 162 Cryptococcus neoformans isolates from Cuba.
AID567441	Antifungal activity against Trichosporon domesticum after 48 hrs by broth microdilution method	2010	Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9	In vitro antifungal activities of isavuconazole and comparators against rare yeast pathogens.
AID559000	Ratio of AUC to MIC in mouse infected with Candida albicans FA/6862 at 2.03 mg/kg, sc QID	2009	Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8	Pharmacokinetics and pharmacodynamics of a novel triazole, isavuconazole: mathematical modeling, importance of tissue concentrations, and impact of immune status on antifungal effect.
AID519514	Antifungal activity against Candida sp. isolates after 48 hrs by CLSI M27-A2 procedure based assay	2008	Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4	In vitro antifungal activities of isavuconazole (BAL4815), voriconazole, and fluconazole against 1,007 isolates of zygomycete, Candida, Aspergillus, Fusarium, and Scedosporium species.
AID557632	Fungicidal activity against Mucor	2009	Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4	In vitro activity of Isavuconazole against Aspergillus species and zygomycetes according to the methodology of the European Committee on Antimicrobial Susceptibility Testing.
AID519506	Antifungal activity against Syncephalastrum isolates assessed as lowest compound concentration that produced complete inhibition of microbial growth after 24 hrs by CLSI M38-A procedure based assay	2008	Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4	In vitro antifungal activities of isavuconazole (BAL4815), voriconazole, and fluconazole against 1,007 isolates of zygomycete, Candida, Aspergillus, Fusarium, and Scedosporium species.
AID519469	Antimicrobial activity against Cryptococcus albidus by broth microdilution method	2008	Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4	In Vitro activity of the new azole isavuconazole (BAL4815) compared with six other antifungal agents against 162 Cryptococcus neoformans isolates from Cuba.
AID525190	Antimicrobial activity against Cryptococcus neoformans by Etest method	2008	Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8	Evaluation of Etest method for determining isavuconazole MICs against Cryptococcus gattii and Cryptococcus neoformans.
AID519519	Antifungal activity against Aspergillus terreus isolates by Etest	2008	Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4	In vitro antifungal activities of isavuconazole (BAL4815), voriconazole, and fluconazole against 1,007 isolates of zygomycete, Candida, Aspergillus, Fusarium, and Scedosporium species.
AID557616	Antifungal activity against Aspergillus fumigatus hyphae by EUCAST method	2009	Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4	In vitro activity of Isavuconazole against Aspergillus species and zygomycetes according to the methodology of the European Committee on Antimicrobial Susceptibility Testing.
AID519523	Antifungal activity against Absidia isolates by Etest	2008	Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4	In vitro antifungal activities of isavuconazole (BAL4815), voriconazole, and fluconazole against 1,007 isolates of zygomycete, Candida, Aspergillus, Fusarium, and Scedosporium species.
AID519511	Antifungal activity against Scedosporium prolificans isolates assessed as lowest compound concentration that produced slight growth or approximately 25% of that of growth control after 24 hrs by CLSI M38-A procedure based assay	2008	Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4	In vitro antifungal activities of isavuconazole (BAL4815), voriconazole, and fluconazole against 1,007 isolates of zygomycete, Candida, Aspergillus, Fusarium, and Scedosporium species.
AID519509	Antifungal activity against Scedosporium apiospermum isolates assessed as lowest compound concentration that produced slight growth or approximately 25% of that of growth control after 24 hrs by CLSI M38-A procedure based assay	2008	Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4	In vitro antifungal activities of isavuconazole (BAL4815), voriconazole, and fluconazole against 1,007 isolates of zygomycete, Candida, Aspergillus, Fusarium, and Scedosporium species.
AID519525	Antifungal activity against Syncephalastrum isolates by Etest	2008	Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4	In vitro antifungal activities of isavuconazole (BAL4815), voriconazole, and fluconazole against 1,007 isolates of zygomycete, Candida, Aspergillus, Fusarium, and Scedosporium species.
AID557619	Antifungal activity against Aspergillus niger hyphae by EUCAST method	2009	Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4	In vitro activity of Isavuconazole against Aspergillus species and zygomycetes according to the methodology of the European Committee on Antimicrobial Susceptibility Testing.
AID567333	Antifungal activity against Saccharomyces cerevisiae after 5 days by broth microdilution method	2010	Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9	In vitro antifungal activities of isavuconazole and comparators against rare yeast pathogens.
AID519529	Antifungal activity against Candida parapsilosis isolates by Etest	2008	Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4	In vitro antifungal activities of isavuconazole (BAL4815), voriconazole, and fluconazole against 1,007 isolates of zygomycete, Candida, Aspergillus, Fusarium, and Scedosporium species.
AID559003	Ratio of AUC to MIC in mouse infected with Candida albicans FA/6862 at 13.37 mg/kg, sc QID	2009	Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8	Pharmacokinetics and pharmacodynamics of a novel triazole, isavuconazole: mathematical modeling, importance of tissue concentrations, and impact of immune status on antifungal effect.
AID557620	Antifungal activity against Rhizomucor hyphae by EUCAST method	2009	Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4	In vitro activity of Isavuconazole against Aspergillus species and zygomycetes according to the methodology of the European Committee on Antimicrobial Susceptibility Testing.
AID535688	Antibacterial activity against Cryptococcus neoformans serotype AD after 72 hrs by broth microdilution method	2009	Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1	Antifungal susceptibilities among different serotypes of Cryptococcus gattii and Cryptococcus neoformans.
AID567433	Antifungal activity against Saccharomyces cerevisiae after 48 hrs by broth microdilution method	2010	Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9	In vitro antifungal activities of isavuconazole and comparators against rare yeast pathogens.
AID519518	Antifungal activity against Aspergillus niger isolates by Etest	2008	Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4	In vitro antifungal activities of isavuconazole (BAL4815), voriconazole, and fluconazole against 1,007 isolates of zygomycete, Candida, Aspergillus, Fusarium, and Scedosporium species.
AID519520	Antifungal activity against Aspergillus sp. isolates by Etest	2008	Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4	In vitro antifungal activities of isavuconazole (BAL4815), voriconazole, and fluconazole against 1,007 isolates of zygomycete, Candida, Aspergillus, Fusarium, and Scedosporium species.
AID519505	Antifungal activity against Cunninghamella isolates assessed as lowest compound concentration that produced slight growth or approximately 25% of that of growth control after 24 hrs by CLSI M38-A procedure based assay	2008	Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4	In vitro antifungal activities of isavuconazole (BAL4815), voriconazole, and fluconazole against 1,007 isolates of zygomycete, Candida, Aspergillus, Fusarium, and Scedosporium species.
AID567425	Antifungal activity against Rhodotorula mucilaginosa after 7 days by Etest	2010	Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9	In vitro antifungal activities of isavuconazole and comparators against rare yeast pathogens.
AID557625	Fungicidal activity against Aspergillus fumigatus	2009	Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4	In vitro activity of Isavuconazole against Aspergillus species and zygomycetes according to the methodology of the European Committee on Antimicrobial Susceptibility Testing.
AID519530	Antifungal activity against Candida glabrata isolates by Etest	2008	Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4	In vitro antifungal activities of isavuconazole (BAL4815), voriconazole, and fluconazole against 1,007 isolates of zygomycete, Candida, Aspergillus, Fusarium, and Scedosporium species.
AID519522	Antifungal activity against Rhizopus isolates by Etest	2008	Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4	In vitro antifungal activities of isavuconazole (BAL4815), voriconazole, and fluconazole against 1,007 isolates of zygomycete, Candida, Aspergillus, Fusarium, and Scedosporium species.
AID557612	Antifungal activity against Absidia by EUCAST method	2009	Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4	In vitro activity of Isavuconazole against Aspergillus species and zygomycetes according to the methodology of the European Committee on Antimicrobial Susceptibility Testing.
AID519536	Antifungal activity against Fusarium sp. isolates assessed as lowest compound concentration that produced slight growth or approximately 25% of that of growth control after 24 hrs by CLSI M38-A procedure based assay	2008	Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4	In vitro antifungal activities of isavuconazole (BAL4815), voriconazole, and fluconazole against 1,007 isolates of zygomycete, Candida, Aspergillus, Fusarium, and Scedosporium species.
AID519499	Antifungal activity against Mucor isolates assessed as lowest compound concentration that produced slight growth or approximately 25% of that of growth control after 24 hrs by CLSI M38-A procedure based assay	2008	Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4	In vitro antifungal activities of isavuconazole (BAL4815), voriconazole, and fluconazole against 1,007 isolates of zygomycete, Candida, Aspergillus, Fusarium, and Scedosporium species.
AID1873196	Inhibition of ABCG2 (unknown origin) expressed in human HEK293 cells membrane vesicles assessed inhibition of BCRP- mediated transport of 3[H]-E1S for 1 mins using [3H]-estrone sulfate as substrate by liquid scintillation counter analysis	2022	European journal of medicinal chemistry, Jul-05, Volume: 237	Targeting breast cancer resistance protein (BCRP/ABCG2): Functional inhibitors and expression modulators.
AID323598	Antifungal activity against Candida tropicalis bloodstream isolates by broth microdilution method	2007	Antimicrobial agents and chemotherapy, May, Volume: 51, Issue:5	In vitro activities of isavuconazole and other antifungal agents against Candida bloodstream isolates.
AID525543	Antimicrobial activity against Fonsecaea monophora isolates after 72 hrs by CLSI M38-A2 protocol method	2010	Antimicrobial agents and chemotherapy, Apr, Volume: 54, Issue:4	In vitro activities of eight antifungal drugs against 55 clinical isolates of Fonsecaea spp.
AID557610	Antifungal activity against Aspergillus niger by EUCAST method	2009	Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4	In vitro activity of Isavuconazole against Aspergillus species and zygomycetes according to the methodology of the European Committee on Antimicrobial Susceptibility Testing.
AID557622	Antifungal activity against Rhizopus hyphae by EUCAST method	2009	Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4	In vitro activity of Isavuconazole against Aspergillus species and zygomycetes according to the methodology of the European Committee on Antimicrobial Susceptibility Testing.
AID567447	Antifungal activity against Trichosporon sp. after 3 days by broth microdilution method	2010	Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9	In vitro antifungal activities of isavuconazole and comparators against rare yeast pathogens.
AID535685	Antibacterial activity against Cryptococcus neoformans after 72 hrs by broth microdilution method	2009	Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1	Antifungal susceptibilities among different serotypes of Cryptococcus gattii and Cryptococcus neoformans.
AID525188	Antimicrobial activity against Cryptococcus gattii by Etest method	2008	Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8	Evaluation of Etest method for determining isavuconazole MICs against Cryptococcus gattii and Cryptococcus neoformans.
AID323596	Antifungal activity against Candida krusei bloodstream isolates by broth microdilution method	2007	Antimicrobial agents and chemotherapy, May, Volume: 51, Issue:5	In vitro activities of isavuconazole and other antifungal agents against Candida bloodstream isolates.
AID519495	Antifungal activity against Aspergillus sp. isolates after 48 hrs by CLSI M38-A procedure based assay	2008	Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4	In vitro antifungal activities of isavuconazole (BAL4815), voriconazole, and fluconazole against 1,007 isolates of zygomycete, Candida, Aspergillus, Fusarium, and Scedosporium species.
AID525187	Antimicrobial activity against Cryptococcus gattii by broth microdilution method	2008	Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8	Evaluation of Etest method for determining isavuconazole MICs against Cryptococcus gattii and Cryptococcus neoformans.
AID567427	Antifungal activity against Dipodascus capitatus after 3 days by broth microdilution method	2010	Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9	In vitro antifungal activities of isavuconazole and comparators against rare yeast pathogens.
AID558994	Ratio of AUC to MIC in mouse infected with Candida albicans FA/6862 at 0.82 mg/kg, sc QID	2009	Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8	Pharmacokinetics and pharmacodynamics of a novel triazole, isavuconazole: mathematical modeling, importance of tissue concentrations, and impact of immune status on antifungal effect.
AID557615	Antifungal activity against Cunninghamella by EUCAST method	2009	Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4	In vitro activity of Isavuconazole against Aspergillus species and zygomycetes according to the methodology of the European Committee on Antimicrobial Susceptibility Testing.
AID535690	Antibacterial activity against Cryptococcus gattii serotype C after 72 hrs by broth microdilution method	2009	Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1	Antifungal susceptibilities among different serotypes of Cryptococcus gattii and Cryptococcus neoformans.
AID525189	Antimicrobial activity against Cryptococcus neoformans by broth microdilution method	2008	Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8	Evaluation of Etest method for determining isavuconazole MICs against Cryptococcus gattii and Cryptococcus neoformans.
AID557630	Fungicidal activity against Absidia	2009	Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4	In vitro activity of Isavuconazole against Aspergillus species and zygomycetes according to the methodology of the European Committee on Antimicrobial Susceptibility Testing.
AID558996	Ratio of AUC to MIC in mouse infected with Candida albicans FA/6862 at 2.67 mg/kg, sc BID	2009	Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8	Pharmacokinetics and pharmacodynamics of a novel triazole, isavuconazole: mathematical modeling, importance of tissue concentrations, and impact of immune status on antifungal effect.
AID525541	Antimicrobial activity against Fonsecaea isolates after 72 hrs by CLSI M38-A2 protocol method	2010	Antimicrobial agents and chemotherapy, Apr, Volume: 54, Issue:4	In vitro activities of eight antifungal drugs against 55 clinical isolates of Fonsecaea spp.
AID557634	Antifungal activity against Aspergillus fumigatus by broth microdilution method	2009	Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4	In vitro activity of Isavuconazole against Aspergillus species and zygomycetes according to the methodology of the European Committee on Antimicrobial Susceptibility Testing.
AID567428	Antifungal activity against Dipodascus capitatus after 4 days by Etest	2010	Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9	In vitro antifungal activities of isavuconazole and comparators against rare yeast pathogens.
AID519503	Antifungal activity against Absidia isolates assessed as lowest compound concentration that produced slight growth or approximately 25% of that of growth control after 24 hrs by CLSI M38-A procedure based assay	2008	Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4	In vitro antifungal activities of isavuconazole (BAL4815), voriconazole, and fluconazole against 1,007 isolates of zygomycete, Candida, Aspergillus, Fusarium, and Scedosporium species.
AID567448	Antifungal activity against Trichosporon sp. after 4 days by Etest	2010	Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9	In vitro antifungal activities of isavuconazole and comparators against rare yeast pathogens.
AID559001	Ratio of AUC to MIC in mouse infected with Candida albicans FA/6862 at 13.48 mg/kg, sc administered as single dose	2009	Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8	Pharmacokinetics and pharmacodynamics of a novel triazole, isavuconazole: mathematical modeling, importance of tissue concentrations, and impact of immune status on antifungal effect.
AID557624	Antifungal activity against Cunninghamella hyphae by EUCAST method	2009	Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4	In vitro activity of Isavuconazole against Aspergillus species and zygomycetes according to the methodology of the European Committee on Antimicrobial Susceptibility Testing.
AID558989	Antifungal activity against Candida albicans FA/6862 assessed as postantifungal effect at 5 to 100 times MIC by CLSI M27-A2 method	2009	Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8	Pharmacokinetics and pharmacodynamics of a novel triazole, isavuconazole: mathematical modeling, importance of tissue concentrations, and impact of immune status on antifungal effect.
AID558992	Ratio of AUC to MIC in mouse infected with Candida albicans FA/6862 at 3.27 mg/kg, sc administered as single dose	2009	Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8	Pharmacokinetics and pharmacodynamics of a novel triazole, isavuconazole: mathematical modeling, importance of tissue concentrations, and impact of immune status on antifungal effect.
AID557623	Antifungal activity against Mucor hyphae by EUCAST method	2009	Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4	In vitro activity of Isavuconazole against Aspergillus species and zygomycetes according to the methodology of the European Committee on Antimicrobial Susceptibility Testing.
AID1872531	Oral bioavailability in monkey relative to control	2022	European journal of medicinal chemistry, Mar-05, Volume: 231	Synthetic approaches and structural diversity of triazolylbutanols derived from voriconazole in the antifungal drug development.
AID519524	Antifungal activity against Cunninghamella isolates by Etest	2008	Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4	In vitro antifungal activities of isavuconazole (BAL4815), voriconazole, and fluconazole against 1,007 isolates of zygomycete, Candida, Aspergillus, Fusarium, and Scedosporium species.
AID519507	Antifungal activity against Syncephalastrum isolates assessed as lowest compound concentration that produced slight growth or approximately 25% of that of growth control after 24 hrs by CLSI M38-A procedure based assay	2008	Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4	In vitro antifungal activities of isavuconazole (BAL4815), voriconazole, and fluconazole against 1,007 isolates of zygomycete, Candida, Aspergillus, Fusarium, and Scedosporium species.
AID558988	Antifungal activity against Candida albicans FA/6862 assessed as postantifungal effect at 2 times MIC by CLSI M27-A2 method	2009	Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8	Pharmacokinetics and pharmacodynamics of a novel triazole, isavuconazole: mathematical modeling, importance of tissue concentrations, and impact of immune status on antifungal effect.
AID557635	Antifungal activity against Aspergillus flavus by broth microdilution method	2009	Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4	In vitro activity of Isavuconazole against Aspergillus species and zygomycetes according to the methodology of the European Committee on Antimicrobial Susceptibility Testing.
AID1817557	Antifungal activity against Aspergillus fumigatus ATCC 204305 assessed as inhibition of fungal growth incubated for 24 hrs by broth microdilution method	2021	Journal of medicinal chemistry, 07-22, Volume: 64, Issue:14	Identification of Thiazoyl Guanidine Derivatives as Novel Antifungal Agents Inhibiting Ergosterol Biosynthesis for Treatment of Invasive Fungal Infections.
AID558997	Ratio of AUC to MIC in mouse infected with Candida albicans FA/6862 at 1.34 mg/kg, sc QID	2009	Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8	Pharmacokinetics and pharmacodynamics of a novel triazole, isavuconazole: mathematical modeling, importance of tissue concentrations, and impact of immune status on antifungal effect.
AID557638	Plasma concentration in human	2009	Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4	In vitro activity of Isavuconazole against Aspergillus species and zygomycetes according to the methodology of the European Committee on Antimicrobial Susceptibility Testing.
AID558993	Ratio of AUC to MIC in mouse infected with Candida albicans FA/6862 at 1.63 mg/kg, sc BID	2009	Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8	Pharmacokinetics and pharmacodynamics of a novel triazole, isavuconazole: mathematical modeling, importance of tissue concentrations, and impact of immune status on antifungal effect.
AID519526	Antifungal activity against Scedosporium apiospermum isolates by Etest	2008	Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4	In vitro antifungal activities of isavuconazole (BAL4815), voriconazole, and fluconazole against 1,007 isolates of zygomycete, Candida, Aspergillus, Fusarium, and Scedosporium species.
AID558999	Ratio of AUC to MIC in mouse infected with Candida albicans FA/6862 at 4.06 mg/kg, sc BID	2009	Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8	Pharmacokinetics and pharmacodynamics of a novel triazole, isavuconazole: mathematical modeling, importance of tissue concentrations, and impact of immune status on antifungal effect.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Timeframe	Studies, This Drug (%)	All Drugs %
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	20 (5.46)	29.6817
2010's	202 (55.19)	24.3611
2020's	144 (39.34)	2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Publication Type	This drug (%)	All Drugs (%)
Trials	37 (9.84%)	5.53%
Reviews	66 (17.55%)	6.00%
Case Studies	60 (15.96%)	4.05%
Observational	3 (0.80%)	0.25%
Other	210 (55.85%)	84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Clinical Trials (45)

Trial Overview

Trial	Phase	Enrollment	Study Type	Start Date	Status
A Single Center, Open-label Trial of Isavuconazole Prophylaxis Against Invasive Fungal Infection in Patients Undergoing Allogeneic Hematopoietic Stem Cell Transplant (HCT) [NCT03149055]	Phase 2	99 participants (Actual)	Interventional	2017-05-04	Completed
A Phase 1, Open-Label, Sequential Study of the Effect of Multiple Doses of Isavuconazole on the Pharmacokinetics of a Single Dose of Digoxin in Healthy Adult Subjects [NCT01582412]	Phase 1	24 participants (Actual)	Interventional	2012-03-31	Completed
A SINGLE ARM, PROSPECTIVE, MULTI-CENTER STUDY TO EVALUATE SAFETY AND EFFICACY OF ISAVUCONAZOLE FOR PRIMARY TREATMENT OF CHINESE PATIENTS WITH INVASIVE FUNGAL DISEASE (IFD) CAUSED BY ASPERGILLUS SPECIES OR OTHER FILAMENTOUS FUNGI [NCT05630976]	Phase 4	56 participants (Anticipated)	Interventional	2023-02-07	Recruiting
A Phase 1, Open-label, Multicenter, Non-comparative Pharmacokinetics and Safety Study of Intravenous and Oral Isavuconazonium Sulfate in Pediatric Patients [NCT03241550]	Phase 1	49 participants (Actual)	Interventional	2017-10-02	Completed
A Phase 1 Open-Label Mass Balance Study to Evaluate the Pharmacokinetics of BAL8728 After A Single Intravenous Dose of 14C-Labeled Isavuconazonium Sulfate in Healthy Male Subjects [NCT02059590]	Phase 1	6 participants (Actual)	Interventional	2013-04-30	Completed
A Phase 1 Randomized Open Label, Parallel Group Study to Evaluate the Effect of Multiple Doses of Esomeprazole on the Pharmacokinetics of Isavuconazole [NCT02128893]	Phase 1	24 participants (Actual)	Interventional	2014-01-31	Completed
Phase 1 Study of Ibrutinib and Immuno-Chemotherapy Using Temozolomide, Etoposide, Doxil, Dexamethasone, Ibrutinib, Rituximab (TEDDI-R) in Primary CNS Lymphoma [NCT02203526]	Phase 1	93 participants (Anticipated)	Interventional	2014-08-14	Recruiting
Isavuconazole for the Prevention of SARS-CoV-2-associated Invasive Aspergillosis in Critically-Ill Patients [NCT04707703]	Phase 3	8 participants (Actual)	Interventional	2021-03-16	Terminated(stopped due to Participant enrollment challenges)
A Phase 1 Open Label Study to Evaluate the Effect of Multiple Doses of Isavuconazole on the Pharmacokinetics of Repaglinide and Caffeine [NCT02128321]	Phase 1	24 participants (Actual)	Interventional	2014-01-31	Completed
A Phase III, Double-blind, Randomized Study to Evaluate the Safety and Efficacy of BAL8557 Versus a Caspofungin Followed by Voriconazole Regimen in the Treatment of Candidemia and Other Invasive Candida Infections [NCT00413218]	Phase 3	450 participants (Actual)	Interventional	2007-03-08	Completed
A Phase 1, Open-Label, Sequential Study of the Effect of Multiple Doses of Isavuconazole on the Pharmacokinetics of a Single Dose of Methadone in Healthy Adult Subjects [NCT01582425]	Phase 1	24 participants (Actual)	Interventional	2012-04-30	Completed
Patterns of Real-World Isavuconazole Use, Effectiveness, Safety, and Healthcare Resource Utilization-a Retrospective Chart Review Study of Patients With Mucormycosis or Invasive Aspergillosis (PRISMA) [NCT04550936]		600 participants (Anticipated)	Observational	2021-03-10	Recruiting
A Phase 1, Randomized, Double Blind, Placebo and Active Controlled, Parallel Study to Evaluate the Effect of Repeat Doses of Isavuconazole on Cardiac Repolarization in Healthy Adult Subjects [NCT01565720]	Phase 1	161 participants (Actual)	Interventional	2012-03-31	Completed
A Phase III, Double Blind, Randomized Study to Evaluate Safety and Efficacy of BAL8557 Versus Voriconazole for Primary Treatment of Invasive Fungal Disease Caused by Aspergillus Species or Other Filamentous Fungi. [NCT00412893]	Phase 3	527 participants (Actual)	Interventional	2007-03-07	Completed
A Phase 1, Open-Label, Drug Interaction Study of the Pharmacokinetics of Isavuconazole and Midazolam After Separate and Concomitant Administration to Healthy Adult Subjects [NCT01406171]	Phase 1	24 participants (Actual)	Interventional	2011-05-31	Completed
A Phase 1 Crossover Study to Assess the Bioequivalence of Isavuconazole Following a Single Dose of Isavuconazonium Sulfate Intravenous Solution Via Nasogastric Tube Compared to a Single Dose of Oral Capsules Under Fasting Conditions in Healthy Subjects [NCT04096157]	Phase 1	17 participants (Actual)	Interventional	2019-09-24	Completed
A Phase 1, Open-Label Study to Evaluate the Effect of Multiple Doses of Isavuconazole on the Pharmacokinetics of Metformin [NCT01884558]	Phase 1	24 participants (Actual)	Interventional	2013-02-28	Completed
A Phase 1, Open- Label Study to Evaluate the Effect of Multiple Doses of Isavuconazole on the Pharmacokinetics of Methotrexate [NCT01884636]	Phase 1	24 participants (Actual)	Interventional	2013-02-28	Completed
A Phase 2, Open-Label, Non-Comparative, Multicenter Study to Evaluate the Safety and Tolerability, Efficacy and Pharmacokinetics of Isavuconazonium Sulfate for the Treatment of Invasive Aspergillosis (IA) or Invasive Mucormycosis (IM) in Pediatric Subject [NCT03816176]	Phase 2	31 participants (Actual)	Interventional	2019-08-22	Completed
Effect of Multiple Doses of Isavuconazole on the Pharmacokinetics of a Single Dose of Cyclosporine: A Phase 1, Open-Label, Sequential Study in Healthy Adult Subjects [NCT01494597]	Phase 1	24 participants (Actual)	Interventional	2011-11-30	Completed
A Study of Temozolomide, Etoposide, Doxil, Dexamethasone, Ibrutinib, and Rituximab (TEDDI-R) in Aggressive B-cell Lymphomas With Secondary Involvement of the Central Nervous System (CNS) [NCT03964090]	Phase 2	65 participants (Anticipated)	Interventional	2019-06-27	Recruiting
Translational PKPD Modeling of Anti-infective Drugs in Children Treated in Pediatric Units on the Example of Selected Antibiotics and Antifungals. [NCT05426499]		150 participants (Anticipated)	Observational	2021-10-01	Active, not recruiting
A Phase 1, Open-Label Study to Evaluate the Effect of Multiple Doses of Isavuconazole on the Pharmacokinetics of a Single Dose of Atorvastatin [NCT01635946]	Phase 1	24 participants (Actual)	Interventional	2012-08-31	Completed
Open-label Study of Isavuconazole in the Treatment of Participants With Aspergillosis and Renal Impairment or of Participants With Invasive Fungal Disease Caused by Rare Moulds, Yeasts or Dimorphic Fungi [NCT00634049]	Phase 3	149 participants (Actual)	Interventional	2008-04-22	Completed
LCCC1841: A Pilot Study of Acalabrutinib in Relapsed/Refractory Primary and Secondary CNS Lymphomas [NCT04548648]	Phase 2	16 participants (Anticipated)	Interventional	2020-10-15	Recruiting
Effect of Multiple Doses of Isavuconazole on the Pharmacokinetics of a Single Dose of Tacrolimus: A Phase 1, Open Label, Sequential Study in Healthy Adult Subjects [NCT01535547]	Phase 1	24 participants (Actual)	Interventional	2011-12-31	Completed
A Phase 1 Open Label, 2 Part, Parallel Group Study to Investigate the Effect of Renal Impairment on the Pharmacokinetics of Isavuconazole [NCT01555866]	Phase 1	49 participants (Actual)	Interventional	2012-03-31	Completed
A Phase I, Open-Label, Single and Multiple Dose Study to Assess the Safety and Pharmacokinetics of Isavuconazole in Healthy Chinese Volunteers [NCT01555918]	Phase 1	36 participants (Actual)	Interventional	2012-08-31	Completed
An Open-Label, Fixed Sequence Study in Healthy Subjects to Assess the Pharmacokinetics of Acalabrutinib and Its Active Metabolite, ACP-5862, When Administered Alone and in Combination With Moderate CYP3A4 Inhibitors Fluconazole or Isavuconazole [NCT05140096]	Phase 1	30 participants (Actual)	Interventional	2020-01-03	Completed
A Phase 1, Open-Label Study to Evaluate the Effect of Multiple Doses of Isavuconazole on the Pharmacokinetics of a Single Dose of Bupropion [NCT01635972]	Phase 1	24 participants (Actual)	Interventional	2012-06-30	Completed
A Phase 1, Open-Label, Sequential Study of the Effect of Multiple Doses of Isavuconazole on the Pharmacokinetics of a Single Dose of Dextromethorphan in Healthy Adult Subjects [NCT01651325]	Phase 1	24 participants (Actual)	Interventional	2012-05-31	Completed
A Phase 1, Open-Label, Sequential Study of the Effect of Multiple Doses of Isavuconazole on the Pharmacokinetics of a Single Dose of Warfarin in Healthy Male Subjects [NCT01657825]	Phase 1	20 participants (Actual)	Interventional	2012-06-30	Completed
A Phase 1, Randomized, Open-Label, Two-Arm, Parallel Group Study of the Effect of Ketoconazole at Steady State on the Pharmacokinetics of a Single Dose of Isavuconazole in Healthy Adult Subjects [NCT01657838]	Phase 1	24 participants (Actual)	Interventional	2012-05-31	Completed
A Phase 1, Open Label, Parallel Group, Single Dose Study to Evaluate the Pharmacokinetics of Isavuconazole in Healthy Non-Elderly and Elderly Male and Female Subjects [NCT01657890]	Phase 1	28 participants (Actual)	Interventional	2012-06-30	Completed
A Phase 1, Open-Label, Parallel Study to Evaluate the Effect of Multiple Doses of Isavuconazole on the Pharmacokinetics of Multiple Doses of Lopinavir/Ritonavir and the Effects of Lopinavir/Ritonavir on the Pharmacokinetics of Multiple Doses of Isavuconaz [NCT01660477]	Phase 1	68 participants (Actual)	Interventional	2012-06-30	Completed
A Phase 1, Open-Label, Sequential Study of the Effect of Multiple Doses of Isavuconazole on the Pharmacokinetics of a Single Dose of Mycophenolate Mofetil in Healthy Adult Subjects [NCT01711489]	Phase 1	24 participants (Actual)	Interventional	2012-03-31	Completed
A Phase 1, Open-label, Sequential Study of the Effect of Multiple Doses of Isavuconazole on the Pharmacokinetics of a Single Dose of Prednisone in Healthy Adult Subjects [NCT01711827]	Phase 1	21 participants (Actual)	Interventional	2012-02-29	Completed
Effect of Multiple Doses of Isavuconazole on the Pharmacokinetics of a Single Dose of Sirolimus: A Phase 1, Open-Label, Sequential Study in Healthy Adult Subjects [NCT01809860]	Phase 1	22 participants (Actual)	Interventional	2011-11-30	Completed
A Phase 1 Open-Label Mass Balance Study to Evaluate the Pharmacokinetics of Isavuconazole After a Single Oral Dose of 14C-Labeled Isavuconazonium Sulfate in Healthy Male Subjects [NCT01813461]	Phase 1	8 participants (Actual)	Interventional	2012-10-31	Completed
A Phase II Study of Isavuconazole Prophylaxis in Adult Patients With AML/MDS and Neutropenia [NCT03019939]	Phase 2	65 participants (Actual)	Interventional	2017-03-28	Completed
Open Label, Multi-center, Sequential Group Clinical Study to Determine the Safety and Efficacy of Escalating Dosing Regimens of Intravenous BAL8557 in the Prophylaxis of Patients Undergoing Chemotherapy for Acute Myeloid Leukemia [NCT00413439]	Phase 2/Phase 3	18 participants (Actual)	Interventional	2006-05-31	Completed
Azole-echinocandin Combination Therapy for Invasive Aspergillosis A Randomized Pragmatic Superiority Trial [NCT04876716]	Phase 3	650 participants (Anticipated)	Interventional	2021-05-11	Recruiting
A Phase 1, Open Label Study to Evaluate the Effect of Multiple Doses of Isavuconazole on the Pharmacokinetics of a Single Dose Oral Contraceptive Containing Ethinyl Estradiol and Norethindrone [NCT01597986]	Phase 1	24 participants (Actual)	Interventional	2012-04-30	Completed
Observational Disease Registry of Patients Treated With Systemic Mold-Active Triazoles [NCT03066011]		2,015 participants (Actual)	Observational	2017-03-16	Completed
A Phase 2 Study of VL-2397 Compared to Standard First-Line Treatment for Invasive Aspergillosis in Adults With Acute Myelogenous Leukemia, Acute Lymphocytic Leukemia, or Allogeneic Hematopoietic Cell Transplant Recipients [NCT03327727]	Phase 2	4 participants (Actual)	Interventional	2018-02-20	Terminated(stopped due to Business decision)
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Trial Outcomes

Trial	Outcome
NCT00412893 (10) [back to overview]	Percentage of Participants With a Clinical Response Assessed by the DRC
NCT00412893 (10) [back to overview]	All-cause Mortality Through Day 42
NCT00412893 (10) [back to overview]	All-cause Mortality Through Day 84
NCT00412893 (10) [back to overview]	Number of Participants With Adverse Events, Reported by System Organ Class
NCT00412893 (10) [back to overview]	Percentage of Participants With a Clinical Response Assessed by the Investigator
NCT00412893 (10) [back to overview]	Percentage of Participants With a Mycological Response Assessed by the DRC
NCT00412893 (10) [back to overview]	Percentage of Participants With a Mycological Response Assessed by the Investigator
NCT00412893 (10) [back to overview]	Percentage of Participants With a Radiological Response Assessed by the DRC
NCT00412893 (10) [back to overview]	Percentage of Participants With a Radiological Response Assessed by the Investigator
NCT00412893 (10) [back to overview]	Percentage of Participants With an Overall Outcome of Success Evaluated by the Data Review Committee (DRC)
NCT00413218 (9) [back to overview]	Percentage of Participants With Overall Response of Success at the End of Intravenous Therapy (EOIV) as Determined by the Data Review Committee (DRC) Based on the Assessments of Clinical and Mycological Responses as Well as Alternative Systemic AFT Use
NCT00413218 (9) [back to overview]	Time to First Confirmed Negative Culture
NCT00413218 (9) [back to overview]	All-Cause Mortality (ACM) at Day 14 and Day 56
NCT00413218 (9) [back to overview]	Percentage of Participants With Clinical Response of Success at Day 7 and EOT as Determined by The Investigator
NCT00413218 (9) [back to overview]	Percentage of Participants With Clinical Response of Success at EOIV, EOT, FU1 and FU2 as Determined by the Data Review Committee (DRC)
NCT00413218 (9) [back to overview]	Percentage of Participants With Overall Response of Success at Follow Up Visit 1 (FU1-2 Weeks After End of Treatment (EOT)) as Determined by the DRC Based on the Assessments of Clinical, Mycological Responses and Antifungal Therapy (AFT)
NCT00413218 (9) [back to overview]	Percentage of Participants With Mycological Response of Success at EOIV, EOT, FU1 and FU2 as Determined by the Data Review Committee (DRC)
NCT00413218 (9) [back to overview]	Percentage of Participants With Overall Response of Success at EOT and Follow Up Visit 2 (FU2) as Determined by the DRC Based on the Assessments of Clinical and Mycological Responses as Well as Alternative Systemic AFT Use at EOT and FU2
NCT00413218 (9) [back to overview]	Percentage of Participants With Mycological Response of Success at Day 7 and EOT as Determined by The Investigator
NCT00634049 (9) [back to overview]	Crude Success Rate of Clinical Response to Treatment Evaluated by the Data Review Committee (DRC) at Day 42, 84 and EOT
NCT00634049 (9) [back to overview]	Crude Success Rate of Overall Outcome of Treatment Evaluated by the Data Review Committee (DRC) at Day 42, 84 and End of Treatment (EOT).
NCT00634049 (9) [back to overview]	Crude Success Rate of Mycological Response to Treatment Evaluated by the Investigator at Day 42, Day 84 and EOT
NCT00634049 (9) [back to overview]	Crude Success Rate of Mycological Response to Treatment Evaluated by the Data Review Committee (DRC) at Day 42, 84 and EOT
NCT00634049 (9) [back to overview]	Crude Success Rate of Clinical Response to Treatment Evaluated by the Investigator at Day 42, Day 84 and EOT
NCT00634049 (9) [back to overview]	All-cause Mortality Through Day 42 and Day 84
NCT00634049 (9) [back to overview]	Crude Success Rate of Radiological Response to Treatment Evaluated by the Data Review Committee (DRC) at Day 42, 84 and EOT
NCT00634049 (9) [back to overview]	Crude Success Rate of Radiological Response to Treatment Evaluated by the Investigator at Day 42, Day 84 and EOT
NCT00634049 (9) [back to overview]	Safety - Overall Number of TEAEs
NCT03019939 (11) [back to overview]	Number of Participants With Other Invasive Fungal Infections (IFIs)
NCT03019939 (11) [back to overview]	Invasive Fungal Infections (IFIs)-Free Survival
NCT03019939 (11) [back to overview]	Number of Participants Who Failed Treatment
NCT03019939 (11) [back to overview]	Number of Participants With Death Related to Invasive Fungal Infections (IFIs)
NCT03019939 (11) [back to overview]	Number of Participants With Invasive Aspergillosis
NCT03019939 (11) [back to overview]	Number of Participants With Proven or Probable Invasive Fungal Infections (IFIs)
NCT03019939 (11) [back to overview]	Number of Participants With Treatment Success
NCT03019939 (11) [back to overview]	Overall Survival (OS)
NCT03019939 (11) [back to overview]	Time to Death From Any Cause
NCT03019939 (11) [back to overview]	Time to Diagnosis of Proven or Probable Invasive Fungal Infections (IFIs)
NCT03019939 (11) [back to overview]	Time to Initiation of Empiric Anti-fungal Therapy
NCT03816176 (11) [back to overview]	Pharmacokinetics of Isavuconazonium Sulphate in Plasma: Trough Concentration (Ctrough)
NCT03816176 (11) [back to overview]	Percentage of Participants With Mycological Response: AC Assessment
NCT03816176 (11) [back to overview]	Percentage of Participants With Overall Response: Adjudication Committee (AC) Assessment
NCT03816176 (11) [back to overview]	Percentage of Participants With Clinical Response: Investigator Assessment
NCT03816176 (11) [back to overview]	Number of Participants With Treatment Emergent Adverse Events (TEAEs)
NCT03816176 (11) [back to overview]	Percentage of Participants With Clinical Response: AC Assessment
NCT03816176 (11) [back to overview]	Percentage of Participants With All - Cause Mortality
NCT03816176 (11) [back to overview]	Percentage of Participants With All - Cause Mortality Through Day 42
NCT03816176 (11) [back to overview]	Percentage of Participants With Radiological Response: AC Assessment
NCT03816176 (11) [back to overview]	Percentage of Participants With Radiological Response: Investigator Assessment
NCT03816176 (11) [back to overview]	Percentage of Participats With Mycological Response: Investigator Assessment

Percentage of Participants With a Clinical Response Assessed by the DRC

"Blinded assessments of clinical symptoms and physical findings of invasive fungal disease were performed by the independent DRC.~Clinical response is defined as the resolution or partial resolution of all attributable clinical symptoms and physical findings. Failure is defined as no resolution of any attributable clinical symptoms and physical findings and/or worsening. Participants with no attributable signs and symptoms present at Baseline and no symptoms attributable to invasive fungal disease (IFD) developed post-baseline were classified as Not Applicable. End of treatment is the last day of study drug administration." (NCT00412893)
Timeframe: Day 42, Day 84 and End of Treatment. The median duration of study drug administration was 45 days.

Intervention	percentage of participants (Number)
	Day 42 (n=139, 120)	Day 84 (n=141, 124)	End of Treatment (n=137, 121)
Isavuconazole	64.0	46.1	62.0
Voriconazole	57.5	44.4	60.3

Intervention	participants (Number)
	Patients with ≥ 1 TEAE	Gastrointestinal Disorders	Infections and Infestations	General Disorders / Administration Site Conditions	Respiratory, Thoracic and Mediastinal Disorders	Metabolism and Nutrition Disorders	Nervous System Disorders	Skin and Subcutaneous Tissue Disorders	Investigations	Blood and Lymphatic System Disorders	Psychiatric Disorders	Musculoskeletal and Connective Tissue Disorders	Vascular Disorders	Renal and Urinary Disorders	Cardiac Disorders	Eye Disorders	Injury, Poisoning and Procedural Complications	Hepatobiliary Disorders	Immune System Disorders	Neoplasms benign, malignant and unspecified	Ear and Labyrinth Disorders	Reproductive System and Breast Disorders	Endocrine Disorders	Congenital, Familial and Genetic Disorders	Social Circumstances
Isavuconazole	247	174	152	148	143	108	95	86	85	77	70	69	67	55	43	39	33	23	20	19	14	8	5	3	0
Voriconazole	255	180	158	144	147	121	89	110	96	82	86	77	77	58	57	69	39	42	25	31	13	13	3	2	1

Intervention	percentage of participants (Number)
	Day 42 (n=137, 120)	Day 84 (n=140, 122)	End of Treatment (n=137, 121)
Isavuconazole	64.2	41.4	62.0
Voriconazole	61.7	44.3	64.5

Intervention	percentage of participants (Number)
	Day 42	Day 84	End of Treatment
Isavuconazole	39.9	28.0	37.8
Voriconazole	39.5	36.4	41.1

Intervention	percentage of participants (Number)
	Day 42 (n=109, 100)	Day 84 (n=126, 117)	End of Treatment (n=107, 100)
Isavuconazole	52.3	35.7	50.5
Voriconazole	50.0	37.6	55.0

Intervention	percentage of participants (Number)
	Day 42 (n=141, 128)	Day 84 (n=141, 128)	End of Treatment (n=141, 127)
Isavuconazole	28.4	22.0	29.1
Voriconazole	34.4	29.7	33.1

Intervention	percentage of participants (Number)
	Day 42 (n=142, 128)	Day 84 (n=141, 128)	End of Treatment (n=141, 128)
Isavuconazole	45.1	38.3	43.3
Voriconazole	51.6	41.4	47.7

Intervention	Percentage of Participants (Number)
	Day 14 All-cause Mortality	Day 56 All-cause Mortality
Caspofungin (CAS)/Voriconazole	12.4	29.9
Isavuconazole (ISA)	14.6	30.7

Intervention	Percentage of Participants (Number)
	Day 7	EOT
Caspofungin (CAS)/Voriconazole	64.7	78.6
Isavuconazole (ISA)	54.3	70.9

Intervention	Percentage of Participants (Number)
	Success- End of Intravenous Treatment (EOIV)	Success- End of Treatment (EOT)	Success- Follow-up Visit 1 (FU1)	Success- Follow-up Visit 2 (FU2)
Caspofungin (CAS)/Voriconazole	84.1	84.6	67.7	58.2
Isavuconazole (ISA)	76.4	76.4	67.8	52.8

Intervention	Percentage of Participants (Number)
	Success-EOIV	Success-EOT	Success-FU1	Success-FU2
Caspofungin (CAS)/Voriconazole	85.6	87.6	65.7	56.7
Isavuconazole (ISA)	70.9	71.9	66.8	51.8

Intervention	Percentage of Participants (Number)
	EOT (Day 56)	FU2 (6 weeks after end of treatment)
Caspofungin (CAS)/Voriconazole	72.1	48.3
Isavuconazole (ISA)	61.3	43.2

Intervention	percentage of participants (Number)
	Day 42- Success Rate	Day 84 - Success Rate	End of Treatment (EOT) - Success Rate
mITT - Aspergillus [Not Renally Impaired]	75.0	25.0	66.7
mITT - Aspergillus [Renally Impaired]	55.0	45.0	55.0
mITT - Mucorales (Intolerant)	50.0	50.0	50.0
mITT - Mucorales (Primary Therapy)	50.0	40.0	55.6
mITT - Mucorales (Refractory)	33.3	22.2	22.2
mITT- Other Dimorphic Fungi	79.3	82.8	82.1
mITT- Other Mould Species Only	71.4	42.9	85.7
mITT- Other Non-Candida Yeast	70.0	70.0	70.0
mITT-Other Filamentous Fungi	68.8	62.5	81.3
mITT-Other Mixed Infection	42.9	35.7	38.5

Intervention	percentage of participants (Number)
	Day 42	Day 84	End of Treatment (EOT)
mITT - Aspergillus [Not Renally Impaired]	66.7	50.0	66.7
mITT - Aspergillus [Renally Impaired]	46.7	44.4	50.0
mITT - Mucorales (Intolerant)	25.0	20.0	66.7
mITT - Mucorales (Primary Therapy)	50.0	21.4	42.9
mITT - Mucorales (Refractory)	28.6	25.0	28.6
mITT- Other Dimorphic Fungi	70.6	80.0	76.9
mITT- Other Filamentous Fungi	69.2	64.3	78.6
mITT- Other Mould Species Only	83.3	42.9	66.7
mITT- Other Non-Candida Yeast	50.0	25.0	50.0
mITT-Other Mixed Infection	18.2	33.3	25.0

Intervention	percentage of participants (Number)
	All-cause Mortality Through Day 42	All-cause Mortality Through Day 84
Not Renally Impaired	16.1	20.7
Renally Impaired	22.0	30.5

Intervention	participants (Number)
	TEAEs	Study Drug-Related TEAEs	Serious TEAEs	Study Drug-Related Serious TEAEs	TEAEs Leading to Permanent Discontinuation of Stud	Study Drug TEAEs Leading to Perm Discontinuation	TEAEs Leading to Death	Study Drug-Related TEAEs Leading to Death	Deaths	Deaths Through 28 Days after Last Dose Study Drug
Isavuconazole	139	60	89	13	19	7	44	1	47	42

Intervention	Nanograms/milliter (ng/mL) (Mean)
	Age group 1 to <6 Day 7	Age group 1 to <6 Day 14	Age group 6 to <12 Day 7	Age group 6 to <12 Day 14	Age group 12 to <18 Day 7	Age group 12 to <18 Day 14
Isavuconazonium Sulfate	2965.0	2286.7	3732.7	3623.3	3862.2	4380.0

Intervention	Percentage of participants (Number)
	Day 42 Success	Day 42 Failure	Day 42 Not Evaluable	Day 42 No Assessment	Day 84 Success	Day 84 Failure	Day 84 Not Evaluable	Day 84 No Assessment	EOT Success	EOT Failure	EOT Not Evaluable	EOT No Assessment
Isavuconazonium Sulfate	19.35	3.23	35.48	41.94	19.35	0	16.13	64.52	35.48	12.90	51.61	0

isavuconazole

Description

Cross-References

Synonyms (59)

Research Excerpts

Overview

Effects

Actions

Treatment

Toxicity

Pharmacokinetics

Compound-Compound Interactions

Bioavailability

Dosage Studied

Roles (3)

Drug Classes (6)

Protein Targets (9)

Potency Measurements

Inhibition Measurements

Biological Processes (59)

Molecular Functions (30)

Ceullar Components (28)

Bioassays (158)

Research

Studies (366)

Market Indicators

Research Demand Index: 62.66

Study Types

Clinical Trials (45)

Trial Overview

Trial Outcomes

Percentage of Participants With a Clinical Response Assessed by the DRC

All-cause Mortality Through Day 42

All-cause Mortality Through Day 84

Number of Participants With Adverse Events, Reported by System Organ Class

Percentage of Participants With a Clinical Response Assessed by the Investigator

Percentage of Participants With a Mycological Response Assessed by the DRC

Percentage of Participants With a Mycological Response Assessed by the Investigator

Percentage of Participants With a Radiological Response Assessed by the DRC

Percentage of Participants With a Radiological Response Assessed by the Investigator

Percentage of Participants With an Overall Outcome of Success Evaluated by the Data Review Committee (DRC)

Percentage of Participants With Overall Response of Success at the End of Intravenous Therapy (EOIV) as Determined by the Data Review Committee (DRC) Based on the Assessments of Clinical and Mycological Responses as Well as Alternative Systemic AFT Use

Time to First Confirmed Negative Culture

All-Cause Mortality (ACM) at Day 14 and Day 56

Percentage of Participants With Clinical Response of Success at Day 7 and EOT as Determined by The Investigator

Percentage of Participants With Clinical Response of Success at EOIV, EOT, FU1 and FU2 as Determined by the Data Review Committee (DRC)

Percentage of Participants With Overall Response of Success at Follow Up Visit 1 (FU1-2 Weeks After End of Treatment (EOT)) as Determined by the DRC Based on the Assessments of Clinical, Mycological Responses and Antifungal Therapy (AFT)

Percentage of Participants With Mycological Response of Success at EOIV, EOT, FU1 and FU2 as Determined by the Data Review Committee (DRC)

Percentage of Participants With Overall Response of Success at EOT and Follow Up Visit 2 (FU2) as Determined by the DRC Based on the Assessments of Clinical and Mycological Responses as Well as Alternative Systemic AFT Use at EOT and FU2

Percentage of Participants With Mycological Response of Success at Day 7 and EOT as Determined by The Investigator

Crude Success Rate of Clinical Response to Treatment Evaluated by the Data Review Committee (DRC) at Day 42, 84 and EOT

Crude Success Rate of Overall Outcome of Treatment Evaluated by the Data Review Committee (DRC) at Day 42, 84 and End of Treatment (EOT).

Crude Success Rate of Mycological Response to Treatment Evaluated by the Investigator at Day 42, Day 84 and EOT

Crude Success Rate of Mycological Response to Treatment Evaluated by the Data Review Committee (DRC) at Day 42, 84 and EOT

Crude Success Rate of Clinical Response to Treatment Evaluated by the Investigator at Day 42, Day 84 and EOT

All-cause Mortality Through Day 42 and Day 84

Crude Success Rate of Radiological Response to Treatment Evaluated by the Data Review Committee (DRC) at Day 42, 84 and EOT

Crude Success Rate of Radiological Response to Treatment Evaluated by the Investigator at Day 42, Day 84 and EOT

Safety - Overall Number of TEAEs

Number of Participants With Other Invasive Fungal Infections (IFIs)

Invasive Fungal Infections (IFIs)-Free Survival

Number of Participants Who Failed Treatment

Number of Participants With Death Related to Invasive Fungal Infections (IFIs)

Number of Participants With Invasive Aspergillosis

Number of Participants With Proven or Probable Invasive Fungal Infections (IFIs)

Number of Participants With Treatment Success

Overall Survival (OS)

Time to Death From Any Cause

Time to Diagnosis of Proven or Probable Invasive Fungal Infections (IFIs)

Time to Initiation of Empiric Anti-fungal Therapy

Pharmacokinetics of Isavuconazonium Sulphate in Plasma: Trough Concentration (Ctrough)

Percentage of Participants With Mycological Response: AC Assessment

Percentage of Participants With Overall Response: Adjudication Committee (AC) Assessment

Percentage of Participants With Clinical Response: Investigator Assessment

Number of Participants With Treatment Emergent Adverse Events (TEAEs)

Percentage of Participants With Clinical Response: AC Assessment

Percentage of Participants With All - Cause Mortality

Percentage of Participants With All - Cause Mortality Through Day 42

Percentage of Participants With Radiological Response: AC Assessment

Percentage of Participants With Radiological Response: Investigator Assessment